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Abstract
The prevalence of aging-related retinal degenerative disorders is rising amongst
human populations and the origins and early mechanisms of retinal disease remain poorly
understood. A model of premature aging, the harlequin mouse, was used to test the
hypothesis that parainflammation, a response to inflammation correlates with functional
deficits preceding observed structural losses. In vivo retinal imaging showed thinning of
the outer nuclear layer, the earliest retinal structural biomarker observable, while
quantitative gene expression assays showed increases in mRNA levels of the Major
Histocompatibility Complex-I, a marker of both increased inflammation and microglial
activation. In situ immunohistochemistry showed greater numbers of activated resident
microglial cells present in the harlequin versus wild type mouse retina at a young age. A
parainflammatory response as an early disease mechanism opens the door to explore the
efficacy of known anti-inflammatory therapies and better understand the link between
aging and vision loss.

Keywords: harlequin mouse, retinal degeneration, parainflammation, in vivo imaging,
quantitative gene expression, immunohistochemistry, microglial cells, Major
Histocompatibility Complex-I, retinal layer thinning

iii

Co-Authorship
The work presented in this thesis was performed by Justin Mayers under the supervision
and financial support of Dr. Kathleen Hill and Dr. Cindy Hutnik. All of the experimental
work presented in this thesis was performed by Justin Mayers. Dr. Kathleen Hill and Dr.
Cindy Hutnik will be a co-author on all publications for help with all experimental design
and editing.

iv

Acknowledgements
I would like to thank the people who helped guide, motivate and make my life
easier and happier as I marched down the path towards my Master’s degree. My
wholehearted thank you goes to Dr. Kathleen Hill who was invaluable as a supervisor as I
worked through my project. Her positive attitude and willingness to help at any time were
essential as I progressed through my work and overcame any speed bumps I had along the
way. Dr. Hill helped me explore the many perspectives of scientific research and was very
supportive as I refined my skills in the lab. I would also like to thank my co-supervisor
Dr. Cindy Hutnik who provided a different perspective on my work through the clinical
world. Her support and positive reinforcement were necessary to help me build
confidence especially as a public speaker. I would also like to thank the members of my
advisory committee, Dr. Sashko Damjanovski and Dr. Andrè Lachance for providing
valuable advice throughout the course of my project.
The technical expertise of Kelly Galloway-Kay and Darcy O’Neill was instrumental
in my ability to section tissues effectively. I would also like to thank all of the members of
the Hill Lab present and past. The technical assistance of my colleagues and peers in the
lab was instrumental towards finding my comfort level in the lab when working with new
techniques.
To my family and friends, your support was what got me through the cold winters
and hot summers of the past two years as I wasn’t always around, but knew I could
always go home.

v

Table of Contents
Certificate of Examination

ii

Abstract

iii

Co-Authorship

iv

Acknowledgements

v

Table of Contents

vi

List of Figures

xiii

List of Tables

xv

Appendices

xvi

List of Abbreviations

xvii

Chapter 1. Introduction

1

1.1. As demographics shift, human vision loss is a growing concern

1

1.2. The origins and mechanisms of retinal degenerative disorders are unclear

1

1.3. Mouse models are used as human mimics in vision research

3

1.4. The mouse eye is a good mimic of the human eye

4

1.5. The phototransduction process is compromised in models
of retinal degeneration

9

1.6. Electroretinography is a technique that quantifies retinal
function in vivo

10

1.7. The harlequin (hq) mouse is a model of premature aging

10

vi

1.8. Functional deficits precede structural losses hq mouse
neurodegeneration

13

1.9. Apoptosis-inducing factor resembles an oxidoreductase

14

1.10. Complex I disorders cause a reduction of oxidative phosphorylation activity

15

1.11. Aging is associated with increases in oxidative stress

16

1.12. Oxidative stress is common amongst retinal and
neurodegenerative disorders

16

1.13. Inflammatory responses are common in neurodegenerative
disorders

19

1.14. Parainflammation has been associated with retinal degeneration

20

1.15. Inflammation in the retina is associated with large-scale changes in
gene expression

22

1.16. Microarray study of hq retina shows upregulation of genes related
to inflammation

22

1.17. Major Histocompatibility Complex-I is a potential molecular
marker of parainflammation in the retina

23

1.18. Xanthine dehydrogenase is a potential molecular marker of
parainflammation associated with a downstream immune response

25

1.19. Microglial cells are the resident macrophages of the retina and
nervous system

27

1.20. Microglial cells mediate the response to inflammation in the retina

28

1.21. Non-invasive in vivo imaging with Spectral domain-optical
coherence tomography to examine retinal thickness differences

31

vii

1.22. Hypothesis- Early activation of the parainflammatory
response in the hq mouse retina

32

1.23. Experimental Aims

32

Chapter 2. Materials and Methods

35

2.1. Animal Care

35

2.2. Genotyping

35

2.3. Experimental design for in vivo imaging

35

2.4. Anesthesia

36

2.5. In vivo imaging of the posterior mouse eye and retina with
Spectralis® SD-OCT

36

2.6. Spectralis® SD-OCT analysis of fundus and OCT cross-section
of retina images

37

2.7. Statistical analysis of average retinal layer thickness after
in vivo imaging

40

2.8. In vivo imaging with Visante® OCT

40

2.9. Tissue harvesting for RNA extraction

40

2.10. RNA extraction and purification

41

2.11. Taqman® qPCR experimental design

41

2.12. cDNA Synthesis

42

2.13. Taqman® qPCR

42

2.14. Taqman® data analysis

43
viii

2.15. Immunohistochemistry experimental design and tissue processing

44

2.16. Primary and secondary antibodies for immunohistochemistry

45

2.17. Microscopy and analysis of microglial cell counts,
location and morphology

47

2.18. Confocal microscopy

48

Chapter 3. Results

49

3.1. Confirmation of hq mouse phenotype and genotype with the Aif PCR assay

49

3.2. High resolution imaging of the posterior mouse eye with Spectralis® SD-OCT

49

3.3. In vivo imaging with Spectralis® SD-OCT revealed individual
retinal layers

49

3.4. Significant thinning of the hq mouse retina was detected directly
in vivo

58

3.5. In vivo imaging demonstrated hq mouse outer nuclear
layer thinning

58

3.6. Superior and inferior OCT images displayed no significant differences
between retinal layer thicknesses

65

3.7. Downregulation of Aif in the hq mouse was confirmed with quantitative
PCR assays

65

3.8. There was no significant increase in Xdh mRNA levels in the hq mouse
retina and cerebellum vs wild-type

68

3.9. H2-K1 mRNA levels were significantly increased at a young age
in the hq mouse

68

ix

3.10. There was an age-associated increase in !2M mRNA levels

71

3.11. Young hq mice have a greater population of microglial cells

71

3.12. Young hq mice have greater numbers of activated microglial cells

74

3.13. Microglial cells are primarily located in the outer plexiform layer

75

3.14. Microglial cells with different morphology were observed in the hq
and wild-type mouse retinas

79

Chapter 4. Discussion

82

4.1. Early-onset retinal degeneration in the hq mouse is associated
with parainflammation

82

4.2. Spectralis® SD-OCT provides the earliest detection of retinal thinning
in the hq mouse

84

4.3. Retinal thinning is a global event that occurs throughout
the hq mouse retina

85

4.4. The use of in vivo imaging of the mouse is a popular technique to
detect retinal degeneration

85

4.5. Spectralis® SD-OCT produces retinal images comparable to
histological sections

86

4.6. The advantage of in vivo imaging of the mouse retina

87

4.7. Increased numbers of microglial cells were observed in the hq retina
at a young age

88

4.8. The presence of microglial cells in the outer retina was observed
in the hq mouse

89

x

4.9. Gene expression results indicate early activation of the
parainflammatory response

90

4.10. The quantitative gene expression changes of Xanthine dehydrogenase
were inconsistent with previously observed microarray results

91

4.11. Limitations of transcriptome data and qPCR confirmations

92

4.12. Gene expression changes are different in the retina
compared to cerebellum

92

4.13. The young hq retina has similarities to normal, aged mouse
retinas

94

4.14. Increased expression of MHC-I genes demonstrates a greater population
of antigen presenting cells in the hq mouse retina

95

4.15. Microglial cells appearance in the outer retina is a common observation
in models of retinal degeneration

96

4.16. Crosstalk with photoreceptors has been implicated in retinal
microglial activation

98

4.17. Knockout of chemokine signaling results in a similar retinal
degenerative phenotype as the hq mouse

98

4.18. Blood-retina barrier breakdown is a potential inducer of chronic
inflammation in the hq mouse

100

4.19. Location of microglial cells at the outer nuclear layer may be due to
mitochondrial dysfunction

101

4.20. Anti-inflammatory therapy may reduce microglial activation

102

4.21. Therapy to restore mitochondrial function to prevent retinal
degeneration

103

xi

4.22. The hq mouse exhibits characteristics of an early, active response
to parainflammation

104

4.23. Conclusion

104

Bibliography

106

Curriculum Vitae

130

xii

List of Figures
Figure 1.1

Hematoxylin & eosin stained cross-sectional images of the
mouse eye and retina

5

Figure 1.2. Diagram of electroretinogram a-wave and b-wave outputs.

11

Figure 2.1. Schematic diagram of Spectralis® SD-OCT image analysis.

38

Figure 3.1. Average mouse body mass was significantly lower in the
hq mice at all ages

50

Figure 3.2. PCR amplification confirmed the presence of the hypomorphic
mutation of the Aif genotype.

52

Figure 3.3. Spectralis® SD-OCT acquired fundus images comprising a
large area of the posterior of the mouse eye.

54

Figure 3.4. Spectralis® SD-OCT achieved a near histological resolution
of the retinal layers

56

Figure 3.5. Significant thinning of the hq mouse retina was detected at
7 months of age

59

Figure 3.6. Spectralis® SD-OCT images obtained from each age cohort
and genotype

61

Figure 3.7. Significant thinning of the hq mouse retina outer nuclear layer
was detected in vivo

63

Figure 3.8. No differences were observed in hq and wild-type mouse inferior
and superior retinal layer thickness

66

Figure 3.9. Quantitative PCR assays showed increased mRNA levels of
MHC-I components and no changes in Xdh levels

69

Figure 3.10. Greater numbers of microglial cells were observed in the
hq mouse retina

72

xiii

Figure 3.11. Activated microglial cells aggregate in the outer plexiform layer
adjacent to photoreceptor cells in young hq mice.

76

Figure 3.12. Resting microglial cells were observed in the inner retina of
both hq and wild-type mice.

80

Figure B.1. Diagram of the Taqman® qPCR experimental design.

124

Figure B.2. Selection of final antibody concentration was determined
following dilution series of primary and secondary antibodies.

126

Figure B.3. Specificity of the anti-F4/80 primary antibody was
demonstrated in wild-type mouse spleen.

128

xiv

List of Tables
Table B1. List of primers used in PCR experiments

121

Table B2. Retinal and cerebellar RNA sample concentrations

122

xv

List of Appendices
Appendix A. The University of Western Ontario Ethics Approval for
Animal Use in Research

118

Appendix B. Supplementary Tables and Figures

120

xvi

List of Abbreviations
!2M

!-2-Microglobulin

AGEs

Advanced Glycation End Products

Aif

Apoptosis-inducing factor

AMD

Age-Related Macular Degeneration

BRB

Blood-Retina Barrier

Ca2+

Calcium Ion

cGMP

Cyclic Guanosine Monophosphate

CNS

Central Nervous System

ERG

Electroretinogram

Gapdh

Glyceraldehyde 3-Phosphate Dehydrogenase

GCL

Ganglion Cell Layer

hq

harlequin

Iba1

Ionized Calcium Binding Adaptor Molecule 1

IFN-"

Interferon-"

INL

Inner Nuclear Layer

IPL

Inner Plexiform Layer

IS

Inner Segment

MHC-I

Major Histocompatibility Complex-I

xvii

Na+

Sodium Ion

NADH

Nicotinamide Adenine Dinucleotide

NADPH

Nicotinamide Adenine Dinucleotide Phosphate

OCT

Optical Coherence Tomography

ONL

Outer Nuclear Layer

OPL

Outer Plexiform Layer

OS

Outer Segment

PBS

Phosphate-Buffered Saline

RPE

Retinal Pigment Epithelium

ROS

Reactive Oxygen Species

SD-OCT

Spectral Domain Optical Coherence Tomography

SOD

Superoxide Dismutase

TLR

Toll-Like Receptor

TNF-#

Tumour Necrosis Factor-#

VEGF

Vascular Endothelial Growth Factor

WT

Wild-Type with reference to the Apoptosis-inducing factor gene

Xdh

Xanthine Dehydrogenase

XO

Xanthine Oxidase

XhqX

harlequin female carrier mouse

xviii

XhqY

harlequin male disease mouse

xix

1
Chapter 1. Introduction
1.1. As population demographics shift, human vision loss is a growing concern
Providing comprehensive vision care in Canada is becoming more difficult as the
average age in the population increases. Clinicians will see increases in the incidence of
vision disorders, particularly those altering the retina. Diseases such as age-related
macular degeneration, glaucoma and diabetic retinopathy have the highest prevalence
rates of 11%, 3% and 4% in individuals with vision loss.1 There are 500,000 Canadians
over the age of 75 and 150,000 between the age of 65-74 suffering from the umbrella
term of “vision loss”.1 This produces a strain on the healthcare system as the current costs
associated with vision loss on the Canadian Health Expenditure is $8.6 billion.1 These
costs will grow as a larger percentage of Canadians will be over the age of 60 in the next
decade than at any time in the country’s history.2 Thus, as retinal degenerative disorder
prevalence increases, vision research is critical now and in the upcoming decade as the
problem worsens.

1.2. The origins and mechanisms of retinal degenerative disorders are unclear
Many human eye diseases cause progressive retinal degeneration, but the origins
and mechanisms vary across each disorder. In retinal degeneration, structural losses cause
thinning of the retinal layers that result in losses of either central or peripheral vision. In
retinal degenerative disorders, risk and prevalence increase with age. The most prevalent
disorder is age-related macular degeneration (AMD) specifically in older populations
(75+ years).3 The long-term effect of AMD is visual impairment characterized by a loss of
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central vision that can be slow or acute depending on the case. AMD is diagnosed mainly
through clinical examination of the retina and diagnostic tests that include imaging and
angiography. AMD results in a loss of central vision through the accumulation of lipid,
proteins, blood and fibrosis in the subretinal space.4 The biomaterial known as drusen
interferes with normal oxygen transport and microvasculature invades the macula (centre
of retina) and disrupts central vision.4,5 Current treatments include injections of antivascular endothelial growth factor (VEGF) drugs and laser surgery that both attempt to
block the formation of new blood vessels.6 There is a strong genetic link to AMD and
future work could result in a possible genetic test for disease risk.7
Another prevalent disorder, glaucoma ultimately results in a loss of peripheral
vision through damage to the optic nerve.8 A rise in intraocular pressure is a major risk
factor and but is not obligatory in all glaucomas.9 The most consistent finding is cell
losses in the ganglion layer.9 The only known treatment involves strategies to improve
drainage and to slow the production of eye fluid to relieve the pressure on the optic nerve.
10

Unfortunately, these therapies are not a cure and are not effective in some patients.
Other disorders include retinopathies which result from vascular and/or

inflammatory conditions of the retina with many cases caused by diabetes.11 This disease
is diagnosed through clinical examination of the fundus of the eye with an
ophthalmoloscope as well as diagnostic imaging and angiography. Recently, it has been
determined that retinopathies may be classified as genetic disorders, and may not solely
be a response to inflammation.12 Additionally, while the causative triggers have yet to be
discovered, drug trials that target the VEGF pathway have shown promising results in
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treatments.13 Currently, the mechanisms that initiate retinal degenerative disorders are
poorly understood. Ophthalmologists and optometrists have tools to diagnose disorders
mainly through visualizing structural markers. The use of structural markers may be too
late to detect disease onset as the early mechanisms have most likely been activated at
this point.
As disease prevalence increases it is important to explore the yet to be understood
early mechanistic causes of these diseases, as any understanding of early disease
mechanisms will prove invaluable.

1.3. Mouse models are used as human mimics in vision research
Animal models are a pillar of vision research with mouse models being the most
popular choice. Mouse models are an effective research tool due to the ability to
reproduce phenotypes, usage as knockout models and as proof-of-principle prior to
pharmaceutical clinical trials in humans. Advantages of using mice for research include
short generation time, large litters and many genetic and physiological similarities
between mouse and humans.
The structure of the mouse eye and retina have similarities to the human eye
including a large lens, cornea and optic nerve. The retina has similar cell types and
organization between these species. The similarities between mouse and human eyes
outnumber the differences. There are many mouse models used in vision research that
focus on broad ocular issues as they relate to specific disease models. Available mouse
models of retinal degeneration have arisen through both spontaneous single gene
mutations and targeted mutagenesis while genetic screens have identified many of the
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affected genes.14 To date, there are over 150 different ocular mouse models in use and
these model a wide variety of ocular ailments including cataracts, glaucoma and
retinopathies.14 As retinal degenerative disorders rise in prevalence across the human
population, research with mouse models is crucial to explore disease origins and
mechanisms to help discover new potential drug targets for human diseases.

1.4. The mouse eye is a good mimic of the human eye
The vertebrate eye can be divided into an anterior and posterior segment with the
anterior containing various structural elements and the posterior the functional centre
containing the neural retina (Figure 1.1). The neural retina is a complex structure
comprised of a series of cell layers containing cells with different neurological functions.
The retina connects to the central nervous system via the optic nerve. At the base of the
retina is the vascular middle layer of the eye known as the choroid, it is a major but not
the sole blood supply to the retina. The choroid receives blood from the ophthalmic artery
via the branched anterior and posterior ciliary arteries. The blood supply moves from the
choroid to the retina through a monolayer called the retinal pigment epithelium (RPE).
The RPE is a pigmented layer that functions as a homeostatic barrier, nutrient shuttle, a
waste removal site and is the location for recycling of old photoreceptors.15 The cell
membrane of the RPE has infoldings that are crucial to its role as a transport shuttle of
nutrients and other substances between the choroid and the neural retina. The RPE is an
important site of the blood-retina barrier which creates an immune privilege in the retina.
The RPE also contains an abundance of mitochondria implicating it as a site
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Figure 1.1. Hematoxylin & eosin stained cross-sectional images of the mouse eye and
retina. (A) A hematoxylin & eosin stained cross-section acquired at 2X magnification of
the whole mouse eye which exhibits a large lens and cornea. (B) Hematoxylin & eosin
stained mouse retina acquired at 20X magnification with layers labelled as follows:
Ganglion Cell Layer (GCL), Inner Plexiform Layer, (INL), Inner Nuclear Layer (INL),
Outer Plexiform Layer (OPL), Outer Nuclear Layer (ONL), Outer Segment (OS), Inner
Segment (IS) and Retinal Pigment Epithelium (RPE). (B) Hematoxylin & eosin stained
mouse retina of a 10 month old hq mouse, where structural losses in the ONL have
occurred. (C) Light (represented by the yellow arrow) passes through the retina and is
absorbed by the photoreceptors. The outer nuclear layer features the cell bodies of the
photoreceptors. The electrochemical signal is passed to the bipolar cells via synaptic
connection in the outer plexiform layer. The signal passes through the bipolar cell bodies
located in the inner nuclear layer. A synapse is formed in the inner plexiform layer
between bipolar cells and amacrine and ganglion cells. The ganglion cells relay the signal
to the brain through the optic nerve.
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of large scale metabolic activity.
The photoreceptors are found in the outer retina and the nuclei of these cells form
the outer nuclear layer. There are two types of photoreceptors known as rod and cone
cells named for their morphological appearance. The photoreceptors consist of an inner
and outer segment and the nuclei. The nuclei are separated from the inner and outer
segments by an external limiting membrane. This separation is a result of the formation of
junctional complexes between Müller glia cells and photoreceptors. Müller glia are
neuronal support cells that regulate retinal homeostasis and are located throughout the
retina. The inner segment of the photoreceptors features a high number of mitochondria
along with glycogen and ribosomes, indicative of high metabolic activity in these
segments resulting in a recycling of the photoreceptor cells.
The cell bodies of the photoreceptor cells comprise the outer nuclear layer (ONL).
The photoreceptor cell rod and cone axons form a synapse with the neural cells of the
inner nuclear layer (INL). The synapses form a thin layer called the outer plexiform layer
(OPL) that is internal to the outer nuclear layer. The synapses are formed by a horizontal
cell process that extends between the photoreceptor and bipolar cells. The inner nuclear
layer contains the nuclei of four different cell types; bipolar, horizontal, Müller and
amacrine cells. Of these four cell types, the bipolar cells are the most abundant. The
bipolar cells form synapses with both the photoreceptor cells and the ganglion cells,
acting as a synaptic mediator between the inner and outer retina. The synapses that form
between the bipolar and amacrine cells with the ganglion cells occur in the inner
plexiform layer (IPL). The ganglion cell layer (GCL) is a dense layer of neuron cells with
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a higher cell density closest to the optic nerve. The ganglion cell layer contains the nuclei
of these cells and is thinner than the other nuclear layers in the retina. The axons that form
the optic nerve arise from the nerve fiber layer. These ganglion cell axons do not have a
myelin sheath inside the eye and are surrounded by two types of glial cells known as
astrocytes and Müller cells.
In total, three types of glial cells exist in the retina. These are the microglial,
astrocyte and Müller cells each with significant functions. Microglial cells are the resident
macrophages that comprise the immune response to injury, stress or foreign cells.
Microglial cells are derived from the mesodermal germ layer as opposed to the neuron
cells of the retina which are derived from the ectodermal germ layer. Astrocytes are long,
thin cells that are essential to the physical support system of the retina and also connect
the neurons and the blood-retina barrier.16 Müller cells are also neuronal support cells.
The three types of glial cells present in the vertebrate retina have different roles, but are
essential to proper retinal function and organization.
Though they share many components, there are several distinguishing
characteristics between mouse and human eyes. The mouse eye is smaller in size but the
mouse lens is larger relative to the human lens. Two main structural differences are the
lack of both a macula and the lamina cribrosa in mice, the latter being a sieve-like
extracellular matrix through which the optic nerve axons exit the eye. The lamina
cribrosa is the anatomical location at which in humans, glaucoma becomes most
clinically evident. The macula is found in humans and is responsible for central vision
due to its high number of photoreceptors especially cones, and the macula degenerates in
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the advanced stages of AMD. In mice, the lack of a macula is countered with a higher
density of photoreceptors, mainly rods in the central retina.17 The lack of these structures
is a major reason why mouse models are an inexact replicate of the human eye. A further
difference is the mouse photoreceptor layers, mainly composed of low light sensing rod
cells (~95%) as mice are nocturnal animals. Thus mice have a higher abundance of rod
photoreceptors relative to cones compared to humans.15

1.5. The phototransduction process is compromised in models of retinal
degeneration
All photons of light pass through all layers of the retina to the outer segment
before reaching the photoreceptor layer (Figure 1.1). The conversion of light to an
electrical signal occurs through chemical changes in the rod photoreceptor’s surface
which is coated with the photopigment rhodopsin.18 Rhodopsin contains an opsin, a light
sensitive G-protein-coupled receptor which absorbs the light.18 The photopigment also
contains an 11-cis-retinal chromophore, that absorbs visible light and reflects or transmits
other types of light. When light is absorbed by the opsin protein, the 11-cis-retinal is
converted to trans-retinal. The conversion activates the transducin component of a Gprotein-coupled receptor.19,20 Active transducin activates phosphodiesterases which
reduce the concentration of cGMP in the photoreceptor.21 Reduction in cGMP
concentration causes a hyperpolarization of the photoreceptor cells by closing the Na+ and
Ca2+ channels whereby the release of the neurotransmitter glutamate is inhibited.21,22
Hyperpolarization of the photoreceptor cells results in a subsequent depolarization of the
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downstream bipolar cells and this signal is transmitted through the amacrine cells to the
ganglion cell layer.21,22 The ganglion cells send the signal to the brain where the signals
initiated from the absorbance of light are processed in the brain and a visual interpretation
is constructed. The integrity of the phototransduction process is important for normal
retinal functioning. Deficits in the ability of the retina to effectively absorb light and
transmit neuronal signals results in vision loss and decreases retinal integrity.

1.6. Electroretinography is a technique that quantifies retinal function in vivo
The physiology of the retina can be assessed in vivo with electroretinography
(ERG). The efficiency of the retinal function is assessed in response to flashes of
escalating light intensity. An electrode is placed on the cornea and measures the electrical
responses to the light stimuli. The two primary outputs obtained from the ERG represent
the two major physiological events of the phototransduction process (Figure 1.2). The awave represents the negative potential of the hyperpolarization of the photoreceptors.23
The b-wave is related to the positive potential caused by the depolarization of the bipolar
neurons.24 This technique is used in both humans and mice and is an important technique
when studying the functional aspects of retinal degeneration.

1.7. The harlequin (hq) mouse is a model of premature aging
The mouse model featured in this study is the harlequin (hq) mouse. The hq
mouse is a model of premature aging characterized by early cerebellar and retinal
degeneration. The hq mouse contains a spontaneous mutation in the Apoptosis-inducing
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Figure 1.2. Diagram of electroretinogram a-wave and b-wave outputs. (A) An
electroretinogram output of an individual with a healthy retina is shown. The a-wave
represents the hyperpolarization of the photoreceptor cells and is the initial negative
component. The b-wave represents the depolarization of the photoreceptor cells and is
represented by the positive portion of the secondary component of the output. The
oscillatory potentials are represented by the waves found between the a-wave and b-wave.
The oscillatory potentials represent amacrine cell function. The x-axis is the time course
of the light pulse in ms. The y-axis is the evoked potential that is measured in µV. (B) An
unhealthy retina output is shown where deficits in the wave amplitude of all three markers
are evident.
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factor (Aif) gene found on the X-chromosome.25 The mutation is caused by a proviral
insertion in the first intron of Aif and results in an 80% downregulation of Aif in all
tissues.25 The result of the mutation is a severe disease genotype (XhqY and XhqXhq) and a
less severe female heterozygous carrier (XhqX). The hq mouse is considered a model of
premature aging due to the presence of several phenotypic markers associated with aging,
including a low body mass, a patchy coat, ataxia, and early-onset retinal and cerebellar
degeneration.25

1.8. Functional deficits precede structural losses in hq mouse neurodegeneration
The hq mouse features early-onset retinal and cerebellar degeneration which have
been elucidated from both a functional and structural perspective. Results of ERG tests
revealed functional deficits in the hq mouse retina as early as 2 months of age.26 These
results did not correlate with any structural damage in the retina. Hematoxylin and eosin
staining reveals that the first evidence of structural change occurs at 4 months where a
thinning of the outer nuclear layer occurs.26 There is also displacement of nuclei from the
outer nuclear layer to the outer plexiform layer. A nuclear displacement was also observed
in the outer segment of the hq retina. Thinning of the inner nuclear layer is not seen in
histological sections until 8 months of age. Disease effects are severe by 10 months of age
where the hq mouse has lost retinal function and the retina has thinned considerably. The
hq mouse displays retinal functional deficits before structural losses indicating that the
disease is initiated through a physiological process and then manifests in the retinal
structure changes as age progresses.25,26 There is also early degeneration of neurites in the

14
hq cerebellum at 2 months of age.27 The loss of granule neurons in the cerebellum at 4
months of age occurs at the same time as those cells in the retina. The loss of neurites at 2
months is a functional deficit that occurs prior to the loss of granule neurons at 4 months
causing neuron death in the cerebellum.27 Both the retinal and cerebellar phenotypes in
the hq mouse show early physiological deficits before structural losses in the neurons
indicating that the disease mechanism lies within the physiological mechanisms.

1.9. Apoptosis-inducing factor resembles an oxidoreductase
The mouse Apoptosis-inducing factor gene is found on the X-chromosome and
encodes a 67 KDa flavoprotein.28 AIF protein is localized to the intermembrane space of
the mitochondria. AIF has two major functions when found in different areas of the cell.
When AIF is translocated to the nucleus, it is an important mediator of caspaseindependent apoptosis.28 In the nucleus, AIF is activated by pro-apoptotic signals causing
chromatin condensation and nuclear fragmentation. When AIF is localized to the
mitochondria, the protein acts as an oxidoreductase.28 There is sequence homology
between AIF and bacterial NADH oxidases and purified AIF exhibits oxidoreductase
activity through electron transfer and the ability to react with oxygen to form superoxide.
28,29 A notable

element of this finding is that NADH oxidases are usually associated with

maintenance of intracellular homeostasis indicating that AIF may be an integral part of
the oxidative phosphorylation.29 However, AIF does not possess a hydrogen peroxide
scavenger activity as do other oxidases. Experiments with the hq mouse have shown that
restoration to wild-type decreases sensitivity to hydrogen peroxide but there is no
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evidence that AIF is directly involved.25 A disruption of intracellular homeostasis and an
ability to generate superoxide shows that Aif downregulation in the hq mouse is
associated with increased oxidative stress.25

1.10. Complex I disorders feature a reduction of oxidative phosphorylation activity
The hq mouse is a good model of mitochondrial dysfunction that can be used to
explore disease mechanisms. The hq mouse is a model of interest for deficiencies in the
respiratory chain complex I which account for approximately 30-40% of mitochondrial
diseases.30 The hq mouse displays similar features to complex I disorders such as
cerebellar ataxia, low body mass, optic atrophy and retinitis pigmentosa.30 An
investigation of complex I activity showed that the hq mouse featured an overall
deficiency but the severity differed across tissues.30 The tissue with the lowest activity of
complex I is the retina with the hq mouse having only 25% residual activity when
compared to wild-type.30 While protein gel analysis showed that AIF is not a member of
complex I, the hq mouse shows a reduced protein abundance and expression of complex
I, mainly in the cerebellum and retina.31 These results indicated that AIF plays a role in
either the assembly or function of complex I in oxidative phosphorylation. The
downregulation of AIF in the hq mouse compromises oxidative phosphorylation possibly
disrupting cellular homeostasis.
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1.11. Aging is associated with increases in oxidative stress
As organisms age, oxidative stress levels increase as reactive oxygen species
(ROS) accumulate. ROS contain an unstable electron that is able to react with biological
molecules such as lipids, proteins and nucleic acids. As ROS levels increase, there is
greater cellular damage and ROS is considered to be a disease-causing mechanism.32
Diseases such as atherosclerosis and diabetes have been associated with elevated
production of ROS. The failure of cells to maintain homeostasis is associated with
increased ROS production. Processes such as oxidative phosphorylation produce ROS
though there are also detoxifying enzymes such as superoxide dismutase and catalase that
remove ROS from the system.32 As cells age, the pathways to remove ROS from the
system may not function properly and the delicate balance is disrupted resulting in higher
concentrations of ROS.

1.12. Oxidative stress is common amongst retinal and neurodegenerative disorders
The mitochondria are the major site of ROS production and oxidative
phosphorylation is the primary source. This has led many to label mitochondria a
biological clock, and that as age increases, oxidation and antioxidant defenses within
mitochondria do not perform as efficiently. ROS are produced in the mitochondria mainly
through the activity of complex I and III which form a “supercomplex”.33 These
complexes act as a catalyst for the oxidation of NADH by coenzyme Q during oxidative
phosphorylation.33 A by-product of NADH oxidation is the formation of radicals, mainly
highly reactive superoxide, that are readily converted to hydrogen peroxide.33 ROS
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species produced in oxidative phosphorylation react with DNA, lipids and proteins
causing considerable damage to the cell.34 DNA from both the nucleus and mitochondria
is damaged through mutations, which are either single base pair or larger deletions and
have been linked to aging and neurodegenerative diseases.34 Proteins, specifically
enzymes, are affected by ROS-directed post-translational modifications resulting in an
impaired or reduced enzyme activity.35 Older mice contain greater amounts of
polyunsaturated fatty acids and cell membrane lipids are susceptible to damage by ROS.36
The mitochondria cell membrane lipids are especially prone to oxidative stress.
Increasing damage to the mitochondrial membranes, proteins and DNA by ROS will
increase the amount of ROS produced by the mitochondria.37 Mitochondria are also a
source of nitric oxide which reacts with both superoxide anion and hydrogen peroxide
causing further damage to the organelle through peroxynitrite production.38,39
Oxidative stress damage has been linked to common neurodegenerative disorders
where protein oxidation has been observed. Alzheimer’s disease, the most common
neurodegenerative disorder features increased levels of protein carbonyls in the affected
neurons, considered a marker for oxidative stress.40 Parkinson’s disease also contains high
levels of protein carbonyls across all brain regions and there is evidence of peroxynitrite
protein damage in animal models.41 Amyotrophic lateral sclerosis has shown protein
carbonyl accumulation as well as increases in protein nitration in brain tissues.42 Thus
most common neurodegenerative disorders all have underlying links to oxidative stress as
possible causes, with the source of ROS being the mitochondria.
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Research focusing on retinal degenerative disorders has also showed oxidative
stress as a contributor to disease pathogenesis. These disorders contain no mutations in
genes encoded in mitochondrial DNA yet are still associated with mitochondrial
dysfunction.43 AMD is one of the leading causes of blindness in the developed world and
is linked with increases in ROS. As the retina ages, there is an accumulation of lipofuscin,
a product of oxidation of unsaturated fatty acids in the RPE.44 There is a positive
association between retinal aging and increases in oxidative stress but it is unknown
whether it is a disease causing mechanism. Promising evidence of ROS involvement in
AMD has come from a mouse model with a knockout of Superoxide Dismutase 1/2
(SOD1/2), two antioxidants that remove superoxide anions.45 The knockout results in the
development of an AMD-like phenotype in the mice. These results indicate that a loss of
antioxidant activity can be linked with an AMD-like pathology and overwhelming levels
of oxidative stress could be responsible for the disease.45
A novel biomarker for oxidative stress has recently been discovered as a
contributing factor for diabetic retinopathy.46 Prohibitin is a mitochondrial chaperone
protein upregulated in response to oxidative stress that is necessary to stabilize respiratory
enzymes and maintain mitochondrial integrity.46 Upregulation of prohibitin protein in
aging and diabetic retinal cells implies that oxidative stress may be a contributor to
disease progression.46
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1.13. Inflammatory responses are common in neurodegenerative disorders
The term inflammation refers to a cellular response featuring a dynamic network
of events and signals leading to a complex defense response implicated in many different
diseases including Alzheimer’s disease, AMD and diabetic retinopathy. The common
initiators of inflammation are mainly tissue injury or infection and result in activation of a
response to repair damaged tissue.47 An inflammatory response is activated in a cell when
homeostasis is lost and allows a host to adapt to abnormal conditions until repairs are
finished and normal functions return. A successful response to inflammation results in a
mixture of tissue resident and recruited macrophages to mediate repairs.48 Responses are
not continuous, but an inability to restore homeostasis and repair injuries results in a
chronic response characterized by formation of a granuloma which is an accumulation of
macrophages.49
Inflammatory responses from both endogenous and exogenous sources within a
cell are able to induce a signal network. The exogenous sources can be microbial, mainly
viruses and bacteria or non-microbial such as allergens, toxic compounds and foreign
invaders. Endogenous inducers of inflammation include signals released from necrotic or
apoptotic cells, advanced glycation end products (AGEs) and disruptions of cellular
barriers.50 The different classes of inducers activate mediators of inflammation that are
derived from either cells or plasma. There are different classes of mediators including
cytokines and chemokines. Cytokines such as Tumour Necrosis Factor-! (TNF-!) and
Interferon-" (IFN-") are signaling molecules produced by macrophages with an ability to
activate leukocytes or white blood cells, the resident immune cells.49 Chemokines are
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smaller cytokines and assist leukocytes with both movement through chemotaxis and
extravasation, the leakage of white blood cells from surrounding capillaries to injury sites.
49

1.14. Parainflammation has been associated with retinal degeneration
Inflammatory responses are usually induced by a tissue injury or stress, however
there is an additional form called parainflammation lacking these initiators. A
parainflammatory response is associated with a tissue malfunction resulting from
environmental factors or mutations.51 The response is generally low grade but an inability
to overcome the malfunction may lead to activation of a severe, chronic response.51 There
are several human diseases featuring a low-grade yet chronic inflammatory response
including neurodegeneration, asthma, atherosclerosis and type 2 diabetes. Normal
conditions require a low-grade inflammatory response to act in a housekeeping role.
Resident macrophages constantly remove waste and maintain homeostasis in the cell.51 A
main risk factor for transformation to a chronic response is age. As tissues age, the
malfunction persists and the macrophages work harder to clear debris.51 While signals
that initiate a chronic response to inflammation are unknown, a candidate is age-related
increases in oxidative stress.
The retina is a complex neuronal network affected by age-related changes,
specifically increases in oxidative stress. Parainflammatory responses exist within the
retina and triggers include apoptosis of microglial cells and a breakdown of the bloodretina barrier which leaks inflammatory plasma proteins in the retina.52 Oxidative stress
may be an additional trigger where ROS and reactive nitrogen species act as either direct
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or indirect stimuli by activating resident macrophages. Reactive nitrogen species are
produced in the retina and include nitric oxide and its byproducts nitrate, nitrite,
peroxynitrite and peroxyl radical.53 Studies have shown that nitric oxide causes
neurodegeneration, apoptosis and cytotoxicity.53 Reactive oxygen species such as
hydrogen peroxide, hydroxyl radical and superoxide are also produced in the retina and
accumulate with age.53 Age-related oxidative stress is associated with parainflammatory
responses in the retina which activate microglial cells, cytokines and chemokines.
Age is a major risk factor for common retinal degenerative disorders and
parainflammatory-like responses have been observed in these diseases. A young AMD
retina has a similar pathology to a normal aged retina including inflammation inducers
such as complement and microglial activation and macrophage invasion from the choroid.
A recent study showed a relationship between oxidative stress and AMD in mice.54
Lesions in the mouse retina resembling an AMD pathology were formed by exposure to
the oxidated lipid carboxyethylpyrole implicating oxidative stress as a potential initiator
of AMD.54 Models of glaucoma have demonstrated increased superoxide and nitric oxide
production in the mitochondria forming peroxynitrite and ultimately causing ganglion cell
death.54 Oxidative stress is not considered a cause of glaucoma but rather a downstream
effect, implicating inflammation as a mediator of the disease.55 Diabetic retinopathy is
triggered by hyperglycemia which induces oxidative stress and AGEs, two inflammation
activators.50 The blood-retina barrier is broken down in diabetic retinopathy which is
another sign of the response. Aging in the retina is associated with increases in oxidative
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stress and recent studies with common eye diseases show a link between a
parainflammatory response and disease activation.

1.15. Inflammation in the retina is associated with large-scale changes in gene
expression
Inflammation exerts a strong response in the mouse retina and this has been
quantified at the molecular level with gene expression studies. There are many methods
of inducing inflammation and there are a variety of studies on disease models, induced
injuries and normal mouse aging. One study explored gene expression differences
between 3 and 20 month old C57/BL mouse retinas using a microarray.56 Expression
changes and subsequent pathway analysis showed that two of the major groups with
differential expression are the immune response and tissue stress response genes.56 The
upregulated genes include those involved with leukocyte activation, chemotaxis,
phagocytosis, complement and microglial activation.56 These results show that aging is
correlated with increases in inflammatory pathway retinal gene expression in a mouse
model lacking an injury or ocular abnormality.

1.16. Microarray study of hq retina shows upregulation of genes related to
inflammation
The harlequin mouse was chosen for a microarray study to measure differential
gene expression changes associated with the Aif downregulation. A Mouse Gene 1.0 ST®
(Affymetrix, Applied Biosystems Carslbad, California) compared expression levels
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between 5 week and 4 month hq mice and age-matched wild-type in both the cerebellum
and retina.57 There were almost 300 genes with differential expression at 4 months of age
in the retina. Pathway analysis showed changes in expression for genes related to
mitochondrial function, extracellular matrix remodeling and inflammation.57
Inflammation-associated genes included Glial fibrillary acid protein (Gfap) and Aldehyde
dehydrogenase 2 (Aldh2). Additionally, the two Major Histocompatibility Complex-I
genes H2-K1 and !2M were significantly upregulated. These two genes are from an
immune response complex and a known marker of microglial activation.58 Another gene
of interest with differential expression at 4 months of age is Xanthine dehydrogenase
(Xdh) which is related to inflammation as it is activated by pro-inflammatory cytokines.
The results from the hq mouse microarray study showed increases in mRNA levels of the
major pathways and key genes consistent with an active parainflammatory response in
this mouse model.

1.17. Major Histocompatibility Complex-I is a potential molecular marker of
parainflammation in the retina
The Major Histocompatibility Complex-I (MHC-I) is a highly polymorphic
transmembrane bound immunoglobulin family of proteins. The complex consists of both
heavy and light chain polypeptides encoded by the H2-K1 and !2M genes respectively.
The MHC-I is expressed on the surfaces of all nucleated cells and acts as a mediator
between leukocytes and cells suffering from a tissue injury or stress. The role of the
MHC-I is to present an antigenic peptide to cytotoxic T-cells with the heavy and light
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chains forming a complex that bind the foreign peptide on the cell surface. Expression of
the MHC-I was always believed to be confined to only immune specific cells, but mouse
brain and retina neuron cells also express MHC-I.59 New roles for MHC-I have been
hypothesized due to changes in expression in developing neurons linking the immune
system with neuron signaling.59 Synaptic plasticity has also been linked with MHC-I
expression due to dynamic expression in the mouse brain during these events.59 Normal
aging has also shown MHC-I upregulation in 30-month-old rat neuron and glial cells.60
Another association with inflammation is the ability of MHC-I to interact with proinflammatory cytokines though additional co-factors are required for this interaction that
could either inhibit or stimulate immune responses.61
Microarray studies of gene expression changes in the retina of different animal
models have shown that the MHC-I immune response genes, H2-K1 and !2M are altered
in disease and injury models. Both MHC-I genes are significantly upregulated at 20
months in the aged C57/BL mice.56 Normal aging leads to a parainflammatory response
and increased expression of H2-K1 and !2M appears to be a marker for activation of
these pathways when there is no tissue stress or injury.56 Additionally, a study of
differential gene expression in a tissue stress model showed similar candidate genes. Here
the stress was a detachment of the retina in a porcine model and alterations in gene
expression were assessed 24 hours after injury.62 Genes involved in local tissue immune
and inflammatory responses were upregulated after the injury suggesting that these
pathways may be involved with the dynamic changes in the retina after detachment. The
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gene of interest, !2M was significantly upregulated showing that increased MHC-I
expression is not only confined to aging in the retina.62
The DBA/2J is a mouse model of glaucoma which has a low grade inflammatory
response as a disease mediator. A microarray study was conducted with the DBA/2J mice
after increased intraocular pressure was first observed, a hallmark of the disease.63 The
results show genes involved in the immune response and microglial cell activation were
upregulated.63 !2M was also upregulated, offering another connection between the MHCI and large scale changes in gene expression of immune response pathways. The
previously mentioned microarray studies show a unifying response to tissue malfunctions
in the retina whether it is normal aging, injury or disease. The observation of increased
MHC-I mRNA levels in the hq retina microarray implicate these genes as a potential
marker of parainflammation.

1.18. Xanthine dehydrogenase is a potential molecular marker of parainflammation
associated with a downstream immune response
The upregulation of Xanthine dehydrogenase (Xdh) in the hq mouse microarray
led it to be a gene of interest because of its relationship with ROS production and proinflammatory cytokines. Xanthine Dehydrogenase (XDH) is one of the forms of the
Xanthine oxidoreductase enzyme. The enzyme exists in two forms, one being XDH
which is readily converted to Xanthine Oxidase (XO).64 The enzymes are synthesized as
XDH but are interconverted between XDH and XO by either proteolysis or oxidation of
sulfyhydryl residues.64 Both enzymes contain flavoproteins and are members of the
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purine degradation pathway and XDH catalyzes the conversion of hypoxanthine to
xanthine. XO catalyzes the conversion of xanthine to uric acid. The byproduct of these
two reactions is the formation of NADH, superoxide anion and hydrogen peroxide.65 The
conversion of XDH to an oxidase allows the enzyme to produce ROS.65 Superoxide
derived from XO reacts with intracellular nitric oxide and form peroxynitrite which has
been implicated in diseases such as glaucoma.66 A relationship exists between superoxide
and parainflammation and Xdh upregulation in the hq mouse retina could either drive or
mediate the response.
Another link to parainflammation is the pro-inflammatory cytokine mediated
regulation of XDH/XO. The cytokine IFN-" increases both Xdh mRNA production and
XDH enzyme activity in rat liver, endothelial and fibroblast cells.66 These results are a
strong link to the involvement of XDH/XO in immune response mechanisms. The effect
of an upregulation of Xdh can be interpreted as either the enzyme driving or reacting to
inflammation. The mechanism of Xdh as an inducer of parainflammation is through ROS
production.66 The link between ROS production and various eye diseases provides a
reason for why Xdh is a good candidate gene of interest as a marker of retinal
parainflammation. As inflammation is regulated by pro-inflammatory cytokines, this
suggests that the upregulation of Xdh is activated downstream in the the immune
response.66 Activation by cytokines indicates that perhaps the ROS by-products from
XDH may not be activating inflammation, but could be accumulating downstream as the
response becomes chronic.

27
1.19. Microglial cells are the resident macrophages of the retina and nervous system
Microglial cells are the resident tissue macrophages of the nervous system and act
as sentinels, constantly monitoring for tissue injuries or stress. The specific cells in the
mesodermal germ layer are the myeloid or bone marrow cells.67 Microglial cells are
derived from monocytes, which are blood precursor cells and early in development, enter
the nervous system through blood vessel walls.67 The myeloid origin of retinal microglial
cells was confirmed through the presence of a myeloid-specific transcription factor and
shared phenotypic characteristics between the cells.68 Microglial cell populations exist in
the CNS in both a resting and an active state marked by different morphology, gene
expression and behaviours. Resting microglia are surveillance cells that are constantly
motile. The resting cells’ goal is to ensure the CNS is protected from any functional or
structural threats. In the resting state, microglia act as a sensor and are able to
phagocytose any debris or damaged tissues to maintain homeostasis.69,70 Microglial cell
morphology is different than other macrophages with the resting cells featuring ramified
processes protruding from the cell body.71 Upon activation, the morphology changes, and
the branched processes are absorbed in the cell body.71 The activated microglial cell is
more compact and has an amoeboid shape.71
The retina is a component of the central nervous system therefore microglial cells
are present after migrating from the blood early in development. In humans, microglial
cells enter the eye through both the optic disk and the retinal margin.72 Specifically, the
cells enter through the blood vessels of the iris, ciliary body and the retinal vasculature
after crossing the blood-retina barrier (BRB). The cells that enter the retina are precursor

28
cells, and after entrance will differentiate to resting microglia.73,67 During the
developmental period, rat microglial cells are localized to the ganglion, inner plexiform
and inner nuclear layers.74 At a mature age, the cells are only localized to the ganglion
cell and inner plexiform layers.74 The number of microglial cells in the retina is dynamic
and a constant turnover of cells occurs at different rates depending on activation signals.
A study with mice showed that, following an injury, green fluorescent protein-labelled
monocytes cross the BRB and differentiate into microglia.75 The interesting finding was
that over time, the newly derived microglial cells migrated to the outer retina and
subretinal space, the location of the RPE.75 There is a dynamic response to tissue stresses
resulting in migration to the subretinal space.75 Increases in age also show different
localization patterns of microglial cells among normal C57/BL mice.76 Older mice at an
age of 14 months demonstrate a larger distribution of microglial cells in both the inner
plexiform and outer plexiform layers when compared to 3-month-old mice.76 An
additional finding is that in the younger mice, there were no microglial cells found in the
outer retina or subretinal space.76 Microglial cells in the retina are dynamic in terms of
morphology and location.

1.20. Microglial cells mediate the response to inflammation in the retina
Injury or tissue stress are the main activators of retinal microglial cells which
result in a morphological conversion and increased phagocytosis. Activated microglial
cells are also able to release cytokines which are members of the inflammation response
cascade. Analysis of gene expression changes in microglial cells with a microarray
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showed increased mRNA of proinflammatory cytokines, chemokines, complement and
scavenger receptors.77 Triggers of activation include lipopolysaccharide and minor
neuronal damage.77 ROS such as superoxide and oxidized lipids, nucleic acids and
proteins have also been shown to activate microglial cells.78 These ligands are able to
bind Toll-Like Receptor (TLR) family components found on microglial cell surfaces.79
The TLR mediate the response and downstream effects of activation may result in chronic
neurodegeneration or toxicity.79 When pro-inflammatory signals are present, there is a
recruitment of exogenous microglial cells to the retina through the blood-retina barrier
suggesting that cell numbers increase during an active inflammatory response.80
The activation of retinal microglial cells causes a signaling cascade mediated by
the TLR family with the downstream effects having negative consequences for the cells.
Constitutive activation leads to a chronic response to inflammation that is cytotoxic. One
of the downstream effects of microglial activation is the production of ROS.81 Microglial
cells are activated by ROS, however they also possess the ability to create molecules such
as superoxide and nitric oxide.81,82 The production of these molecules in a chronic
inflammatory response causes further damage rather than repair which is the initial goal.
Activated microglial cells are also able to secrete pro-inflammatory cytokines. Cytokines
such as TNF-!, IFN-# and the interleukin family activate downstream immune response
pathways.83 The ability of microglial cells of the retina to secrete cytotoxic molecules is
evidence that microglial activation may be a major cause of neurodegeneration in the
retina. Another feature of activation is the ability of microglial cells to express surface
antigens encoded by the MHC-I genes.58 The ability to present antigens suggests a
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mechanism to mediate inflammatory signals.58 The purpose of antigen presentation is to
interact with T-lymphocytes in the early stages of an immune response. The Tlymphocytes are cytotoxic and MHC-I expression in microglial cells could be a signal
that a chronic response is necessary to destroy foreign, stressed or dying cells in the
vicinity.
Research of the common retinal degenerative disorders resulting from activation
of immune response pathways has shown that microglial activation may contribute to
disease pathology. The effect of the presence of microglial cells was studied with mouse
models of AMD.84 Cell culture studies with cells from the outer retina showed microglial
cells initiate a response to inflammation characterized by the accumulation of cytokines in
this area.84 The downstream response of microglial activation has also been linked with
retinal ganglion cell death, a hallmark of glaucoma. Cultured retinal ganglion cells were
treated with pro-inflammatory cytokines and this treatment increased cell death.85 These
results suggest that the by-products of microglial activation could be a major player in the
progression of glaucoma.85 Another study of the mouse model of glaucoma showed that
microglial cells migrate to the outer retina as the disease progresses.86 This shows that a
dynamic immune response exists in the retina and could be a potential drug target for
glaucoma. A mouse model of retinitis pigmentosa has shown that microglial cells have a
protective role in trying to prevent photoreceptor death, a feature of the disease.87 The
model also shows that continuous microglial activation may also have detrimental effects
on the retina depending on the strength of the pro-inflammatory signals.87 It is still
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unclear whether these responses are all downstream and solely disease effects or whether
microglial activation is driving disease pathogenesis.

1.21. Non-invasive in vivo imaging with Spectral domain-optical coherence
tomography to examine retinal thickness differences
Research of retinal degeneration in mouse models has historically relied on
histology to assess structural changes in the retina. The past decade has seen major
advances in imaging systems commonly found in clinician’s practices but less common in
a research setting. The use of in vivo imaging systems is advantageous as it offers an
opportunity to look inside the living eye. Longitudinal studies are also possible with
reduced animal numbers. When working with mice, in vivo imaging offers a non-invasive
approach to directly visualize changes in the retina. Spectral-domain optical coherence
tomography (SD-OCT) is a technology used to obtain high-resolution images of the
retina. The basis of the SD-OCT technology is a near infrared beam of light that is split
and sent to either a reference position or to the sample.88 The sample beam is reflected off
the ocular tissue of interest and is compared to the reference.88 The coherence and
interference of the two beams are then processed and an image is formed representing the
thickness and density of the tissue.88
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1.22. Hypothesis- Early activation of the parainflammatory response in the hq
mouse retina
The central hypothesis of my work is that parainflammation in the harlequin
mouse retina is associated with both functional deficits and structural losses. The hq
mouse is a model of premature aging and I believe this response is active at an early age
compared to wild-type mice. The 80% downregulation of Aif in the hq mouse is a tissue
malfunction that cannot be overcome with normal inflammation repair systems. As the
mouse ages, the low-grade parainflammatory response will become chronic and have a
detrimental effect on retinal neuron cells.

1.23. Experimental Aims
The first aim is to use high resolution in vivo imaging with Heidelberg Spectralis®
SD-OCT to assess structural losses in the retina from both a focal and a global
perspective. In situ, the hq mouse mouse retina features nuclear displacement and
thinning of the outer nuclear layer as early as 4 months of age. Spectralis® SD-OCT will
be used to establish a timeframe of structural damage as aging progresses. Images will be
taken of the retina both superior and inferior to the horizontal plane of the optic nerve to
determine whether the structural losses occur in a distinct region of the mouse eye. The
images will compare the hq disease and wild-type mice at three different ages. The
youngest age is 1.8 months, which corresponds to when initial functional deficits are
noted but where no structural damage is expected. Mice at 4 months of age are used as a
comparison to the initial appearance of structural alterations, and a small thinning of the
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hq mouse total retina and outer nuclear layer is expected. The final age is 7 months,
where significant structural losses are expected, and this age corresponds to when the hq
disease has progressed and the retina is thinner.
The second aim is to confirm previous microarray results using a quantitative gene
expression assay. The Taqman® real-time polymerase chain reaction assay will be used to
compare and confirm expression changes between hq and wild-type mice. The results of a
previously performed microarray study in the retina and cerebellum were used to assess
genes with significant differences in gene expression at 4 months of age. The genes of
interest in the present study are the MHC-I genes, H2-K1 and !2M as well as the enzyme
Xdh. The MHC-I genes are markers of microglial activation and the immune response and
gene expression values will show at which age these responses are initiated and highly
active. Xdh has been linked with ROS and pro-inflammatory cytokines therefore results
will determine whether the gene is an initiator or a downstream effect of
parainflammation. The assay will be performed with hq and wild-type mice mRNA from
both the retina and the cerebellum. The youngest age used will be 1.8 months, and gene
expression changes in the hq mice will show whether an early response to
parainflammation is present. Mice at 4 months of age will be used to confirm the
microarray results and examine gene expression changes in the earlier stages of hq mouse
retinal degeneration. Mice at 7 months of age will determine the strength of the
parainflamamtory response at the progressive stages of hq mouse retinal degeneration.
The third aim is to use immunohistochemical techniques to count, localize and
assess morphology of microglial cells in the hq mouse retina. Results of this assay will be
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used to infer whether the response to inflammation is active in either hq or wild-type mice
through observation of cell population changes at specific time-points and changes in
location throughout the retina. The primary antibodies anti-Iba1 and anti-F4/80 will be
used to label a microglial cell-surface calcium binding protein and a macrophage specific
cell-surface glycoprotein respectively. Cell counts will be performed to determine relative
abundance between genotypes. The location of the microglial cells at each cohort will be
examined. The morphology of microglial cells will be assessed to classify cells as active
or resting. All age cohorts will be a comparison between hq and wild-type mice retinas.
The youngest age will be 1.8 months, to see if the parainflammatory response is active
from an in situ or cellular perspective at an early age corresponding to the first signs of
neurodegeneration. The second age is 4 months to examine if there is a connection
between the thinning of the retina and microglial activation, specifically the location of
the cells. The final age is 7 months, to observe whether there is a downstream effect of
parainflammation as the severe functional deficits and structural losses have manifested
in the retina.
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Chapter 2. Materials and Methods
2.1. Animal Care
The Canadian Council of Animal Care approved all experimental protocols prior
to the initiation of experimental work (Appendix A). Mice (B6CBACa Aw-J/A- Pcdc8hq/J)
[Jackson Laboratories, Bar Harbor, ME] were housed in a facility kept at a constant
temperature of 21 ± 1° C with a relative humidity of 44-66%. Water and standard diet
[PMI Foods, St. Louis, MO] were delivered ad libitum.

2.2. Genotyping
The genotype of each mouse was determined using a tri-primer polymerase chain
reaction (PCR) protocol.25 DNA was extracted directly from 10-day-old mouse ear
notches. DNA amplified with the terra direct PCR method was used as the main protocol
for genotyping [Clontech, Mountain View, CA]. Amplified DNA was subjected to gel
electrophoresis through a 1.5% agarose gel. The harlequin (hq) disease mouse was
positively identified by the presence of a 725 bp band. Wild-Type mice were identified by
the presence of a 537 bp band.

2.3. Experimental design for in vivo imaging
Male XhqY mice and age-matched wild-type mice at 1.8 months, 4 months and 7
months of age were selected for in vivo imaging. The number of mice per age cohort was
between three and five. The body mass of each mouse was measured prior to in vivo
imaging to determine the required dose of anesthesia. After imaging, the mice were
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euthanized and both eyes harvested for either RNA extraction or placed in fixative for
histological analysis.

2.4 Anesthesia
Mice were anesthetized by an intraperitoneal injection of a mixture of 100 mg/kg
Ketamine hydrochloride (Bioniche Animal Health Canada, Belleville, ON), 5mg/kg
Xylazine hydrochloride (Bayer AG, Leverkusen, Germany) and 1X Phosphate Buffered
Saline (PBS). A subcutaneous injection of 0.01 mg/kg atropine (Ayerst Veterinary
Laboratories, Guelph, ON) was administered immediately after the first injection to
increase the survival rate of anesthetized mice. Atropine was used to prevent the
occurrence of bradycardia, heart failure and bronchiole secretions caused by the
ketamine-xylazine injection.

2.5. In vivo imaging of the mouse eye posterior and retina with Spectralis® SD-OCT
Mice under anesthesia were placed on a heating pad [Petstages, Northbrook, IL] to
maintain a constant body temperature of 37° C. Both pupils were dilated with a single
drop of 0.8% Diophenyl-T [Sandoz Inc, Boucherville, QC] to enable visibility of the back
of the eye. Custom contact lenses [Cantor + Nissel Ltd, Brackley, UK] were placed on the
surface of the Oculus Sinister (OS; left eye) using tweezers. Contact lenses assisted in
maintaining consistent hydration of the eye during imaging. The mouse was removed
from the heating pad and placed on an adjustable platform facing the lens of the
Heidelberg Spectralis® Spectral-Domain Optical Coherence Tomography (SD-OCT)
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[Heidelberg Engineering, Heidelberg, Germany]. The OS was positioned facing the lens
and a drop of Refresh Tears® [Allergan, Markham, ON] was administered to hydrate the
eye which is critical for proper imaging. The mouse eye was positioned with the optic
nerve in the centre of the fundus image. The mouse head was adjusted to position the
optic nerve to obtain multiple images. OCT images of the retinal layers were collected
ranging in 500 µm to 3000 µm both inferior and superior to the optic nerve. After
imaging, mice were transferred to the heating pad for recovery. The contact lens was
removed and a drop of Teargel® [Novartis, Dorval, QC] was placed on each eye,
maintaining hydration during the recovery period.

2.6. Spectralis® SD-OCT analysis of fundus and OCT cross-section of retina images
All in vivo image analysis was performed with the Heidelberg Spectralis® Eye
Explorer Software [Heidelberg Engineering, Heidelberg, Germany]. Images were
classified as inferior or superior to the optic nerve by the location of the OCT retinal
cross-section. The fundus image of the posterior eye was used to measure the distance
between the optic nerve and the retinal cross-section location of the OCT image. The
thickness of the total retina, outer nuclear layer and inner nuclear layer was measured at
three equidistant locations on the cross-section manually with a digital caliper (Figure
2.1).
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Figure 2.1. Schematic diagram of Spectralis® SD-OCT image analysis. All OCT
images acquired with Spectralis® SD-OCT were analyzed with Heidelberg Eye Explorer®
software. (A) The distance of the OCT image from the optic nerve was measured on the
fundus image and is indicated with a red line. For each OCT image, three equidistant
positions along the retina were chosen as retinal layer thickness measurement sites. The
measurements positions fall at 1.0, 2.5 and 4.0 mm on the image scale and are indicated
with green vertical bars. (B) OCT image of a retinal cross-section. Each labelled red bar
indicates a specific measurement recorded at each of the three positions. At each position,
the measurements are total retina thickness (Total), outer nuclear layer thickness (ONL)
and inner nuclear layer thickness (INL).
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2.7. Statistical analysis of average retinal layer thickness after in vivo imaging
The SPSS® (Statistical Package for Social Sciences) software [IBM Inc. Somers,
New York] was used to perform a two-way ANOVA to analyze the average thicknesses of
the total retina, outer nuclear layer and inner nuclear layer across age and genotype
cohorts.

2.8. In vivo imaging with Visante® OCT
The pupils of an anesthetized mouse were dilated with a single drop of 0.8%
Diophenyl-T [Sandoz Inc, Boucherville, QC] and the mouse was transferred to an
adjustable platform. Prior to image capture, the high resolution OCT scan was centered at
the vertex of the mouse eye. The initial image was of the anterior portion of the eye. The
platform was then adjusted to obtain an image of the neuronal retina and retinal pigment
epithelium.

2.9. Tissue harvesting for RNA extraction
Wild-Type and hq mice at ages 1.8 months, 4 months and 7 months were selected
for euthanasia after in vivo imaging. Euthanasia was performed with CO2 gas according to
the Animal Care and Veterinary Services standard operating procedure 320-02. After
euthanasia, both eyes were removed and the retina and cerebellum dissected. Tissues were
flash frozen in liquid nitrogen. All micro-dissection tools were treated with RNAseZAP®
[Sigma Aldrich, Oakville, ON] to prevent RNAse contamination. All tissues were stored
at -80 ° C.
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2.10. RNA extraction and purification
All retinal samples were removed from -80° C storage and RNA was extracted
using a sand homogenization procedure that has been previously described.89 Cerebella
samples were homogenized in a mixture of 30 mg tissue and 1 ml of Qiazol® lysis
reagent. The mixture was subjected to 20 strokes in a glass type-A pestle in a 7 ml
Dounce homogenizer [Wheaton Science Products, Millville, NJ]. After homogenization,
the RNeasy® Mini Spin Column [Qiagen Canada Inc., Montreal, PQ] standard protocol
was used for retinal and cerebellar RNA extraction. RNA was bound to a membrane
within a column followed by subsequent washes with RW1® and RPE® buffers.
Following elution from the RNeasy® column, 25 µl of sodium acetate and 400 µl of 100%
ethanol were added to the RNA samples and stored overnight at -20°C. The samples were
then centrifuged 12000 xg at 4°C for 30 minutes and the supernatant removed. The pellet
was washed twice with 80% ethanol and the sample centrifuged for an additional 30
minutes at 12000 xg at 4°C. The supernatant was then removed and 100 µl of RNAse free
water was added to resuspend the RNA. RNA concentration and purity were assessed
with the Agilent 2100 Bioanalyzer [Agilent Technologies Inc., Palo Alto, CA].

2.11. Taqman® qPCR experimental design
Quantitative PCR experimental design was established to allow a comparison
between RNA expression levels of wild-type and hq disease mice. A total of 3 to 5 mice
of each genotype were selected at 1.8 months, 4 month and 7 month age cohorts. Genes
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were selected based on their identification via a previous microarray study which
demonstrated a significant 2-fold increase in their expression in the hq disease retina and
cerebellum compared to wild-type at 4 months of age (p < 0.05).57 The genes of interest
were H2-K1, B2M and Xdh. A primer set for Aif was also used to confirm the 80%
downregulation of the gene in the hq disease mouse. The Gapdh (glyceraldehyde-3phosphate-dehydrogenase) gene was used as a positive control because it exhibits
consistent expression levels across all tissues.90

2.12. cDNA Synthesis
Mouse RNA samples were selected for a concentration ranging from 100 to 250
ng/µl. The High-Capacity RNA to cDNA kit® [Applied Biosystems, Mountain View, CA]
was used to convert retinal and cerebellar RNA to cDNA. 9 µl of the RNA sample was
added to 10 µl of reverse transcription buffer and 1µl of reverse transcriptase in a PCR
tube. The sample was then transcribed in the Geneamp® PCR System 9700 [Applied
biosystems, Mountain View, CA] with a 60 minute step for synthesis at 90° C and a 5
minute cooling step at 4° C.

2.13. Taqman® qPCR
The qPCR assay was performed in a standard protocol designed for use with the
Taqman® probes. The assay was a block design and all genes of interest were assayed in
parallel with a maximum of 4 mouse samples with 5 genes of interest (Gapdh, Aif, Xdh,
H2-K1, B2M) (Figure B.1.). The genes of interest were assayed in triplicate for every
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mouse sample. Additionally, there was one negative control per gene that did not contain
any mouse transcript. Millipore water was treated with UV light for 5 minutes to destroy
any exogenous DNA present in the sample. DNA free water (100 µl) was added to each
cDNA sample and 4 µl of this mixture was added to a strip tube [Corbett Life Science,
Concorde, NSW]. For each 4 µl volume, 1 µl of Taqman® primer, 5 µl water and 10 µl
Taqman® Master mix were added with a total volume of 20 µl per tube. The assay run was
performed using the ABI 7900 HT Fast Real-Time PCR system [Applied Biosystems,
Mountain View, CA].

2.14. Taqman® data analysis
Taqman® results were analyzed with The $$Ct relative quantitation method to
determine fold changes. The analysis consisted of a comparison of $Ct values from the hq
and wild-type mice. $Ct measured the difference between the average amplification cycle
of each gene with the average amplification cycle of the Gapdh gene. The difference
between the $Ct values of the hq disease and wild-type yielded the $$Ct value. The $$Ct
value was then inserted into the 2-X equation to yield the fold change. A two-way
ANOVA was then performed with SPSS® [IBM Inc. Somers, New York] comparing the
differences between the gene of interest cycle and the Gapdh cycle of both the wild-type
and hq disease and between all of the age cohorts.
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2.15. Immunohistochemistry experimental design and tissue processing
After euthanization with CO2 gas, both mouse eyes were removed with forceps
and immediately placed in an Eppendorf tube containing 1 ml of Telly’s fixative. Telly’s
fixative was comprised of 850 µl of 70% ethanol, 100 µl of 40% formaldehyde and 50 µl
of glacial acetic acid. The fixed eyes were stored at room temperature for a period ranging
from 1 week to 3 months.
The eyes were removed from Telly’s fixative and placed in 70% ethanol. Eyes
were processed with a Leica ASP300 (Leica Microsystems, Houston, TX) automated
tissue processor consisting of serial one hour ethanol dehydrations with 70-100% ethanol.
These steps were followed by a treatment with Xylene overnight. Paraffin was used to
embed the eyes in an orientation known as a C-cut. The C-cut allowed for visualization of
the optic nerve, central retina, pupil and central cornea. Prior to sectioning, blocks were
cooled at 0° C for 1 hour to ensure tissue consistency. The Leica RM2255 Microtome
[Leica Microsystems, Houston, TX] was used to section tissues at 5 µm thickness and 2
sections were placed on positively charged microscope slides [VWR Inc. Mississauga,
ON]. All slides were placed in a 50° C oven overnight to allow the sections to dry.
All slides were deparaffinized prior to the immunohistochemistry experiments.
Deparaffinization was performed by immersing slides in a series of treatments as follows:
2 washes in xylene for 3 minutes each, 1 wash in a 1:1 mixture of xylene and 100%
ethanol for 3 minutes, 1 wash in 100% ethanol for 3 minutes, 1 wash in 95% ethanol for 3
minutes, 1 wash in 70% ethanol for 3 minutes, 1 wash in 50% ethanol for 3 minutes
followed by a rinse in distilled water. Following deparaffinization, slides were immersed
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in ethylene-diamine-tetraacetic (EDTA) acid buffer ph 8.0 consisting of 1 L of distilled
water and 0.37 g of ethylene-diamine-tetraacetic acid for antigen retrieval. Antigen
retrieval was also performed with a microwave by heating the slides at a power level of 4
(40%) for 10 minutes followed by 30 minutes of cooling time. Antigen retrieval involved
heating the sections to 120° C to break protein cross-links that formed during the fixation
step to unmask antigenic epitopes.
All slides were washed in 1X PBS twice for 5 minutes after removal from the
antigen retriever. Sections were incubated for 30 minutes at room temperature in 0.2%
Triton X-100, 10% Normal Goat Serum [Invitrogen, Grand Island, NY]. A blocking step
was essential to prevent the binding of both the primary and secondary antibodies to nonspecific sites. The blocking serum was from a goat host to prevent any non-specific
interactions from the labelled secondary antibody. The Triton X-100 was necessary to
permeabilize the cell membranes and ensure even coverage of the sample.

2.16. Primary and secondary antibodies for immunohistochemistry
After blocking, the sections were washed with 1X PBS twice for 10 minutes. The
sections were then incubated overnight at 4°C with a primary antibody. The primary
antibodies were prepared at a dilution of 1:100 in 1X PBS. The primary antibody mixture
was added to each section. The primary antibodies selected recognize markers of
microglia. Rabbit anti-Ionized Calcium Binding Adaptor Molecule 1 (Iba1) is a marker
for active microglial cells targeting a calcium binding domain on the cell surface [Wako,
Richmond, VA]. The final concentration of primary and secondary antibody used was
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determined by a dilution series experiment (Figure B.2.). The specificity of anti-Iba1 for
microglial cells was demonstrated with 21 month-old wild-type mouse cerebellum tissue
Figure B.2.). Rat anti-F4/80 binds to a membrane glycoprotein found on the surface of the
microglial cells [Serotec, Raleigh, NC]. The specificity of the anti-F4/80 antibody for
microglial cells was assessed with 7 month-old wild-type mouse spleen tissue which have
been previously demonstrated as positive controls (Figure B.3.).91 After primary antibody
incubation, the sections were washed with 1X PBS twice for 10 minutes. The sections
were then incubated with a secondary antibody for 1 to 2 hours at room temperature.
Secondary antibodies were prepared at a dilution of 1:500 in 1X PBS. The secondary
antibody mixture was added to each section in the dark. The secondary antibodies were
conjugated to an Alexafluor® dye and raised in a goat background. The two secondary
antibodies used were goat anti-rabbit Alexafluor-532® and goat anti-rat Alexafluor-488®.
Non-specific antibody binding and autofluorescence were assessed with negative control
slides probed with only secondary antibody.
Following secondary antibody incubation, sections were washed twice in 1X PBS
for 10 minutes. All sections were then coverslipped with Slowfade® Gold Antifade
mounting reagent [Life Technologies, Grand Island NY]. The mounting medium was
applied adjacent to each section and then coverslipped and left at room temperature for 20
minutes to dry.
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2.17. Microscopy and analysis of microglial cell counts, location and morphology
All sections were observed at 200x magnification with the Arcturus Veritas
Microdissection system [Molecular Devices, Sunnyvale, CA]. The whole retina was
observed with the Green and Blue fluorescent filters. Images were taken sequentially of
each retinal segment across the whole retina. The 555 nm filter captured Iba1-positive
cells as the Alexafluor-532® has an excitation wavelength of 532 nm and emittance of 554
nm. The 488 nm filter captured anti-F4/80-positive cells as the Alexafluor-488® has an
excitation wavelength of 495 nm and an emittance of 519 nm. Image analysis was
performed with ImageJ® Software [National Institute of Health, Bethesda, MD]. For each
mouse, a total of five sections were selected with three to five retinal images analysed per
section. A selected rectangular area for each section (115 µm x 75 µm) was calculated
using ImageJ® software. This was used to standardize each observation to account for
different retinal areas due to changes in the curvature of the retina. The rectangle spanned
a region of the retina from the choroid to the ganglion cell layer and had an area of
8681.65 µm%. Yellow (anti-Iba1) or green (anti-F4/80) cells present across the retina were
counted as positive microglial cells. The number of positive cells for each section were
divided by the area of the retina. This value was then averaged for each mouse followed
by an average for each genotype. The number of positive cells per area were then
compared statistically with SPSS® using a two-way ANOVA between the hq and wildtype cell counts.
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2.18. Confocal microscopy
Sections containing a primary antibody mixture and negative controls were
observed at 40x magnification with the Zeiss LSM 5 Duo [Carl Zeiss, Toronto, ON]
confocal microscopy system. Each image spanned the entire retina and images were
acquired at three locations across the retina. The images were examined for the presence
of both resting and active microglial cell morphology.
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Chapter 3. Results
3.1. Confirmation of hq mouse phenotype and genotype with the Aif PCR assay
The observed phenotypic characteristics including a patchy coat and low body
mass were consistent with the hq mouse genotype. The body mass of the hq mice was
lower compared to wild-type at all age cohorts (p < 0.05) (Figure 3.1). The average body
mass of the hq mice at 1.8, 4 months and 7 months was 34%, 32% and 43% lower than
wild-type respectively. 725 bp and 537 bp amplicons confirmed either the presence of a
proviral insertion in the Aif gene or a wild-type mouse respectively (Figure 3.2).

3.2. High resolution imaging of the posterior mouse eye with Spectralis® SD-OCT
Fundus images of the mouse eye acquired with the Spectralis® SD-OCT
successfully obtained images of the posterior mouse eye (Figure 3.3). The Spectralis®
SD-OCT fundus image covered a large area of the posterior retina spanning a diameter of
3.32 mm. In each fundus image, the morphology of the optic nerve and vasculature were
clearly visible. Different regions of the posterior mouse eye were imaged with Spectralis®
SD-OCT by adjusting the position of the optic nerve. The secondary in vivo imaging
system, the Visante® OCT was unable to image the posterior mouse eye.

3.3. In vivo imaging with Spectralis® SD-OCT revealed individual retinal layers
Post-mortem histological images of the mouse retina featured the individual nuclei
of the layers of the retina (Figure 3.4). High resolution in vivo imaging with Spectralis®
SD-OCT resolved the seven individual retinal layers. The Spectralis® SD-OCT images are
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Figure 3.1. Average mouse body mass was significantly lower in the hq mice at all
ages. The mass of each mouse subject was recorded prior to testing (n = 3). Hq mice have
a lower body mass compared to wild-type at each age cohort. Significant differences
between genotypes were observed for each age cohort (* p < 0.05). Error bars represent
+/- one standard error of the mean.
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Figure 3.2. PCR amplification confirmed the presence of the hypomorphic mutation
of the Aif genotype. PCR amplicons were electrophoresed through a 1.5% agarose gel.
The presence of the hq proviral insertion in the Aif gene was confirmed with a 725 bp
PCR amplicon. The wild-type PCR amplicon does not contain the proviral insertion and
was confirmed with a 537 bp PCR amplicon. The heterozygous hq carrier featured the
presence of both the 725 bp and 537 bp PCR amplicons. Product size was estimated using
the Track-it™ 100 bp DNA ladder (Applied Biosystems, Burlington, ON). The negative
control contains water in the master mix in place of mouse DNA.

XhqY

XhqX

WT

WT

WT

WT

XhqX

2072 bp

Negative

53

725 bp
600 bp

100 bp

Wednesday, July 4, 2012

537 bp

54

Figure 3.3. Spectralis® SD-OCT acquired fundus images comprising a large area of
the posterior of the mouse eye. Images of the fundus (anterior surface of the retina) were
obtained in vivo with the Spectralis® SD-OCT. Each image contained the optic nerve
visualized as a dark circle and associated vasculature. The green line represents the
location of the retina where a cross-sectional OCT image was acquired to measure retinal
thicknesses. Images were acquired from the left eye (OS) of (A) 1.8 month hq mouse, (B)
1.8 month wild-type mouse, (C) 4 month hq mouse and (D) 4 month wild-type mouse.
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Figure 3.4. Spectralis® SD-OCT achieved a near histological resolution of the retinal
layers. Images obtained from post-mortem histology, Spectralis® SD-OCT and Visante®
OCT were compared to examine image quality. An image of post-mortem 10 µm
histological sections stained with hematoxylin and eosin was observed from (A) 4 month
hq mouse and (B) 4 month wild-type mouse retinas. The retinal layers and individual
nuclei were visible in these sections. OCT images were acquired with Spectralis® SDOCT of (C) 7 month hq mouse and (D) 7 month wild-type mouse retinas. The individual
retinal layers were visible in these images. OCT images were acquired with Visante®
OCT of (E) 10 month hq mouse and (F) 10 month wild-type mouse retinas. The white
double-sided arrow indicates the visible retinal cross-section limited by the iris.
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similar to post-mortem histological images in terms of retinal layer resolution. The
Visante® OCT was unable to acquire a high resolution image of the retina. The image
only captured the neural retina and the RPE. Images from Visante® OCT featured a 2.40
mm cross-section of the central retina. The Spectralis® SD-OCT obtained fundus images
with a diameter of 3.32 mm. Each image obtained from the Spectralis® SD-OCT
constituted a cross-section of the posterior eye 38% larger than the Visante® OCT.

3.4. Significant thinning of the 7 month old hq mouse retina was detected directly
in vivo
A significant thinning of the hq mouse retina was detected globally among
Spectralis® SD-OCT images both superior and inferior to the optic nerve (Figure 3.5). A
two-way ANOVA showed significant thinning with genotype of the hq mouse total retina
thickness compared to wild-type (p < 0.05). The 7 month old hq mouse had an 8% thinner
retina compared to wild-type.

3.5. In vivo imaging demonstrated hq mouse outer nuclear layer thinning
In vivo imaging with Spectralis® SD-OCT directly demonstrated the thinning of
the outer nuclear layer at 7 months of age (Figure 3.6). A global analysis of OCT images
showed thinning of the hq mouse outer nuclear layer at 7 months of age compared to agematched wild-type mice (p < 0.05) (Figure 3.7). There was no significant difference
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Figure 3.5. Significant thinning of the hq mouse retina was detected at 7 months of
age. The total retina thickness was measured with Heidelberg Eye Explorer® software for
each animal with three replicates per image (n = 4). There was a thinning of the whole
retina in the hq mouse when compared to wild-type. A significant difference was
observed with genotype (p < 0.05). A significant difference between genotypes was
observed for a single age cohort (* p < 0.05). Error bars represent +/- one standard error
of the mean.
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Figure 3.6. Spectralis® SD-OCT images obtained from each age cohort and
genotype. The OCT images obtained from Spectralis® SD-OCT in vivo resolved the
distinct layers of the retina ( GCL- Ganglion Cell Layer, IPL - Inner Plexiform Layer,
INL - Inner Nuclear Layer, OPL- Outer Plexiform Layer, ONL- Outer Nuclear Layer).
Images were acquired from (A) 1.8 month hq mouse and (B) 1.8 month wild-type retinas,
which had no differences in retinal thickness. (C) 4 month hq mouse and (D) 4 month
wild-type mouse retinas also had no differences in retinal thickness. (E) The 7 month hq
mouse had a significantly thinner retina than the (F) 7 month wild-type mouse (p < 0.05).
The black bar in figures (E) and (F) spans the outer nuclear layer where a thinning of this
retinal layer was directly observed with in vivo imaging.
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Figure 3.7. Significant thinning of the hq mouse retina outer nuclear layer was
detected in vivo. OCT images of the hq and wild-type mouse retina both superior and
inferior to the optic nerve were obtained with Spectralis® SD-OCT (n = 4). (A) A
significant difference was observed for both genotype and age (p < 0.05). A significant
difference between genotypes was observed for a single age cohort (* p < 0.05). The hq
mouse outer nuclear layer thinned between the ages of 4 and 7 months. (B) There was no
difference in the inner nuclear layer thickness between hq and wild-type mice at each age
cohort. Error bars represent +/- one standard error of the mean.
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observed in the inner nuclear layer thickness across all ages and genotypes (Figure 3.7).
No thinning was detected of the plexiform layers (data not shown). The results of a twoway ANOVA analysis demonstrated a significant thinning of the outer nuclear layer with
age and genotype (p < 0.05). Between genotypes, the 7 month hq mouse had a 28%
thinner outer nuclear layer compared to that of wild-type mice. In the hq mouse, thinning
of the retina progressed between 4 and 7 months of age. The 7 month hq mouse age
cohort had a 24% thinner outer nuclear layer compared to 4 months of age.

3.6. Superior and inferior OCT images displayed no significant differences between
retinal layer thicknesses
Retinal thickness measurements within each genotype for the total retina, outer
nuclear layer and inner nuclear layer were obtained from Spectralis® SD-OCT images
both superior and inferior to the optic nerve. In both the wild-type and hq mice, there was
no difference in the superior and inferior retinal thickness measurements (Figure 3.8).
Additionally, there was no observed difference in the total retina, outer nuclear layer and
inner nuclear thickness from measurements obtained from the peripheral and central
retina.

3.7. Downregulation of Aif in the hq mouse was confirmed with quantitative PCR
assays
The Aif gene fold-change was quantified in the qPCR assay to confirm the
downregulation of Aif in the hq mouse. The fold-change of the Aif gene in the hq mouse
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Figure 3.8. No differences were observed in hq and wild-type mouse inferior and
superior retinal thickness. Measurements taken from Spectralis® SD-OCT images of
both superior and inferior to the optic nerve of the hq and wild-type mouse retina (n = 3).
(A) There was no difference in total retina thickness within both the wild-type and hq
mouse superior and inferior OCT images at each age cohort. A significant difference
between genotypes was observed for a single age cohort (* p < 0.05). (B) There was no
difference in outer nuclear layer thickness within both wild-type and hq mouse superior
and inferior OCT images at each age cohort. A significant difference between genotypes
was observed for a single age cohort (* p < 0.05). (C) The superior and inferior OCT
images from both hq and wild-type mouse displayed no differences in inner nuclear layer
thickness. The superior and inferior hq mouse outer nuclear layer and total retina was
thinner compared to wild-type at 7 months. Error bars represent +/- one standard error of
the mean.
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retina was 0.03, 0.03 and 0.08 compared to wild-type at 1.8 months, 4 months and 7
months respectively. The fold-change in the hq mouse cerebellum was 0.1, 0.26 and 0.1 in
the previously mentioned age cohorts respectively. A significant difference between
genotypes was detected at all age cohorts (p < 0.05).

3.8. There was no significant increase in Xdh mRNA levels in the hq mouse retina
and cerebellum vs wild-type
The result of the two-way ANOVA in the hq mouse retina and cerebellum revealed
no significant differences in both the age and genotypic cohorts (Figure 3.9). The fold
change of Xdh relative to wild-type in the hq retina at 1.8 months, 4 months and 7 months
of age was 0.14, 1.38 and 1.36 respectively. The fold change in the cerebellum at 1.8
months, 4 months and 7 months was 1.2, 0.3 and 1.4 respectively.

3.9. H2-K1 mRNA levels were significantly increased at a young age in the hq mouse
In the hq mouse retina, the largest fold change of H2-K1 compared to wild-type
was recorded at 7 months (Figure 3.9). The fold change of H2-K1 relative to wild-type in
the hq mouse retina at 1.8 months, 4 months and 7 months was 2.1, 2.2 and 10.2
respectively. The fold change in the hq cerebellum at 1.8 months, 4 months and 7 months
was 1.3, 1.7 and 1.3 respectively. The results of the two-way ANOVA test showed a
significant difference observed with genotype (p < 0.05). The statistical test did not show
an age-associated increase. There were no large fold changes in RNA levels in the hq
cerebellum compared to wild-type. Statistical analysis of the cerebellum results showed
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Figure 3.9. Quantitative PCR assays showed increased mRNA levels of MHC-I
components and no changes in Xdh levels. The Taqman® quantitative gene expression
assay measured differential expression of Xdh, H2-K1 and !2M in the hq mouse retina
and cerebellum (n = 4). (A) There were no significant differences in Xdh levels detected
between both age and genotype. (B) A significant difference in H2-K1 was observed with
genotype in the hq retina (p < 0.05). There was no significant difference in H2-K1 levels
between ages or genotypes in the cerebellum. Significant differences between genotypes
were observed for each age cohort (*p < 0.05). (C) There was a significant interaction
between age and genotype of !2M in the hq mouse retina relative to wild-type ( p <
0.05). A significant difference between genotypes was observed for two age cohorts (* p
< 0.05). There was no significant difference in !2M levels across all ages or genotypes in
the cerebellum.
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no significant differences in mRNA levels in both age and genotype.

3.10. There was an age-associated increase in !2M mRNA levels in the retina
In the hq mouse retina, the !2M fold change compared to wild-type steadily
increased with age (Figure 3.9). There were no significant differences in changes at both
1.8 and 4 months of age in the hq mouse cerebellum. At 7 months of age, the largest fold
change was detected in the cerebellum. The fold change of !2M relative to wild-type in
the hq mouse retina at 1.8 months, 4 months and 7 months was 0.4, 2.2 and 4.6
respectively. The fold change in the hq cerebellum at 1.8 months, 4 months and 7 months
was 1.2, 1.7 and 2.8 respectively. The results of the two-way ANOVA showed a
significant interaction between age and genotype (p < 0.05) in the retina. There was a
steady increase in fold-change with age. The genotypic effect was only seen at 4 and 7
months of age. The statistical tests with the cerebellum data showed no significant
differences with either age or genotype.

3.11. Young hq mice have a greater population of microglial cells
The antibody anti-F4/80 was used as a structural marker for retinal microglial
cells. Anti-F4/80 binds to a membrane bound glycoprotein found on the surface of
macrophages including microglial cells. The results of a two-way ANOVA showed a
significant difference in cell counts observed with genotype (p < 0.05). At each age
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Figure 3.10. Greater numbers of microglial cells were observed in the hq mouse
retina. (A) Based on quantification of images, there were greater numbers of activated
microglial cells labelled with anti-Iba1 at each age cohort in the retinas of hq mice
compared to wild-type (n = 3). A significant difference was observed with genotype and
age (p < 0.05). Significant differences between genotypes were observed for each age
cohort (* p < 0.05). (B) There were greater numbers of microglial cells labelled with antiF4/80 present in the retinas of hq mice when compared to age-matched wild-type (n = 3).
A significant difference was observed with genotype (p < 0.05). Significant differences
between genotypes were observed for two age cohorts (* p < 0.05). Error bars represent
+/- one standard error of the mean.
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cohort, there were increased anti-F4/80 positive cells in the hq mouse compared to wildtype (Figure 3.10). The average number of anti-F4/80 positive cells at 1.8 months of age
in the hq mouse retina was 29% higher than the wild-type control. The cell counts
increased in both genotypes between 1.8 and 4 months of age. At 4 months of age, there
was a 28% increase the number of microglial cells present in the hq mouse retina
compared to that of wild-type mice. Between the ages of 4 and 7 months there was no
significant difference in the number of cells in both hq and wild-type mice. There was a
15% increase in microglial cells at 7 months of age in the hq mouse retina compared to
that of wild-type mice.

3.12. Young hq mice have greater numbers of activated microglial cells
Anti-Iba1 is a functional marker of active microglial cells that binds to a calcium
binding protein on the cell surface. The results of a two-way ANOVA showed a
significant increase in anti-Iba1 positive cells with age and genotype in the hq mouse
compared to wild-type (p < 0.05) (Figure 3.10). At 1.8 months of age, there were 28%
more activated microglial cells present in the hq retina compared to wild-type. There was
a general increase in microglial cell numbers in both hq and wild-type mouse retinas
between 1.8 and 4 months of age with 20% more microglial cells in the hq retina at 4
months. In both hq and wild-type cohorts, there was no increase in microglial cell counts
between 4 and 7 months of age. At 7 months of age, the hq retina had 28% more
microglial cells than the age-matched wild-type mice.
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3.13. Microglial cells are primarily located in the outer plexiform layer
The localization patterns of the anti-Iba1 and anti-F4/80 positive cells were similar
for both antibodies (Figure 3.11). The hq mouse retina had significantly higher cell counts
as early as 1.8 months of age with a similar location of both anti-Iba1 and anti-F4/80
positive cells between both genotypes. The location of the most abundant cell populations
in both genotypes was the outer plexiform layer (Figure 3.11). The microglial cells were
observed in the outer plexiform layer on the border of the nuclei of the outer nuclear
layer. This localization pattern was observed in both hq and wild-type mouse retinas at
1.8 months of age. The higher cell counts in the hq mouse accounted for cells mainly
localized in the outer plexiform layer. At 4 months of age, there was a similar localization
of the microglial cells in both wild-type and hq retina but with higher cell counts in each
genotype. The major difference between the age groups of the hq mice was the evidence
of the structural losses of the outer nuclear layer. In the 4 month hq mouse cohort, there
was a visible structural degeneration of the outer nuclear layer visible with the jagged
edges of the outer nuclear layer. The microglial cells were localized to the region where
cell loss had occurred. The wild-type retina did not feature these structural damages.
However, the microglial cells were located in a similar area. At 7 months of age, the
microglial cells remained in the outer plexiform layer in both hq and wild-type retina with
similar counts as the 4 month cohort. In the hq mouse retina, the structural damage has
progressed and the microglial cells remained located in the region of photoreceptor cell
loss.
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Figure 3.11. Activated microglial cells aggregate in the outer plexiform layer
adjacent to photoreceptor cells in young hq mice. The white arrows are directed at
microglial cells labelled with Anti-Iba1 and Alexafluor-532® secondary antibody. (A) An
image of a 5 µm thick section of a 1.8 month old hq mouse retina treated with anti-Iba1
had a larger population of microglial cells in the outer plexiform layer than a (B) 1.8
month wild-type mouse retina. Both the (C) 4 month old hq mouse retina and (D) 4
month old wild-type mouse retina had the largest microglial cell populations in both
genotypes. The (E) 7 month hq mouse retina had a higher number of activated microglial
cells in the outer plexiform layer and the (F) 7 month wild-type retina featured a
population of resting microglial cells in the inner plexiform layer. (G) Negative control of
a 1.8 month old hq mouse retina that was not treated with Anti-Iba1 and showed only
lipofuscin autofluorescence (indicated with a white arrow) in the segment layer as
expected.
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3.14. Microglial cells with different morphology were observed in the hq and wildtype mouse retinas.
The microglial cells observed in the outer plexiform layer in both genotypes had a
round, amoeboid shape indicative of an activated cell (Figure 3.12). At all age cohorts,
microglial cells with ramified processes were observed in the inner retina of hq and wildtype mice (Figure 3.12). These resting microglial cells were localized to the the inner
plexiform layer. Greater numbers of resting cells in the inner plexiform layer were
observed in wild-type when compared to hq mice.
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Figure 3.12. Resting microglial cells were observed in the inner retina of both hq and
wild-type mice. Two different populations of microglial cells differentiated by
morphology were observed in the hq and wild-type mouse retinas. The white arrowhead
is directed at amoeboid shaped activated, microglial cells. A white arrow is directed at the
resting microglial cells characterized by the presence of ramified processes. The two
types of microglial cells were observed in images obtained from a confocal microscope in
both (A) 4 month old hq mouse retina and (B) 7 month old wild-type mouse retina.
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Chapter 4 - Discussion
4.1. Early-onset retinal degeneration in the hq mouse is associated with
parainflammation

Tissue malfunctions are associated with the cytotoxic effects of parainflammation.
The downregulation of Aif in the hq mouse retina is a unique malfunction in that retinal
degenerative effects are seen at a young age. The timeline of retinal degeneration in the
hq mouse has only been elucidated from phenotypic observations with functional deficits
observed at 2 months followed by structural losses at 4 months of age. The hypothesis
predicted that a response to parainflammation would be active in the hq mouse retina at a
young age. The hq mouse was explored from an in vivo, cellular and molecular
perspective. The results of this study add additional pieces to the hq puzzle specifically by
exploring a potential mechanism for vision loss and photoreceptor cell loss.
At the organismal level, in vivo imaging of the hq mouse retina with Spectralis®
SD-OCT was able to narrow the timeline of structural degeneration that had not been
observed with previous OCT technology. The earliest structural biomarker of hq mouse
retinal degeneration was identified with outer nuclear thinning observed between 4 and 7
months of age. The observation that thinning of the retina, specifically the outer nuclear
layer, from 4 to 7 months in the hq mouse has created a timeframe to explore intervention
strategies aimed at halting or slowing structural degeneration.
At the cellular level, an increased number of microglial cells were present in the
hq mouse retina. This is prior to the early functional deficits observed at 2 months of age.
Microglial cells with a morphology indicative of activation were mainly located in the
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outer plexiform layer. These microglial cells are present in the location where
photoreceptor cell loss occurs throughout the course of the disease.
At the molecular level, quantitative gene expression assays showed an early
increase in MHC-I mRNA levels correlating to early functional deficits. MHC-I is a
molecular marker of microglial activation and the early increases in mRNA levels
correlate to the observation of a greater microglial cell population at this age. The largest
fold-changes of MHC-I were observed between 4 and 7 months of age which is the same
time frame as the outer nuclear thinning observed in vivo.
This study has established a parainflammatory response as a candidate mechanism
of early-onset retinal degeneration in the hq mouse. The addition of the early activation of
microglial cells and increased mRNA levels of MHC-I results to the hq mouse timeline of
neurodegeneration has linked chronological events associated with the early functional
deficits and structural losses. The breakdown of the blood-retina barrier and subsequent
invasion of the retina by lymphocytes is a potential mechanism of early activation of
parainflammation that can be tested with an Evan’s Blue assay and
immunohistochemistry. The time points of the parainflammatory-related observations
offer a window of therapeutic intervention that can be assessed with the hq mouse. Antiinflammatory drugs are an interesting therapy to explore with the hq mouse to observe
whether inflammatory mechanisms can be inhibited to subsequently restore retinal
function. Many ocular ailments feature a form of a response to inflammation. It is unclear
at this point whether inflammatory responses initiate disease pathology or are a
downstream effect.
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4.2. Spectralis® SD-OCT provides the earliest detection of retinal thinning in the hq
mouse
In vivo imaging with Spectralis® SD-OCT has detected the earliest structural
biomarker of retinal degeneration in the hq mouse compared to the Visante® OCT.26 OCT
image measurements showed a significant thinning of the outer nuclear layer between the
ages of 4 and 7 months in the hq mouse. This is consistent with results of post-mortem
analysis of Hematoxylin and eosin stained retinas.26 Post-mortem analysis has
demonstrated structural degeneration in both the whole hq mouse retina and specifically
the outer nuclear layer which is initially detected at 4 months of age.26 The thinning of the
outer nuclear layer is the only significantly different structural change between 4 and 7
months. This suggests that the outer nuclear layer may be the site of action for the
initiating factors of early-onset retinal degeneration in the hq mouse. The significant
thinning of the outer nuclear layer detected in the hq mouse indicates that the disease is
progressing in the time period of 4 to 7 months.
The initial observation of reduced a-wave and b-wave ERG amplitude before
structural losses indicates that photoreceptor cell loss is a downstream effect.26 The
initiating factors of hq mouse photoreceptor degeneration are unclear. In vivo imaging
with Spectralis® SD-OCT has established a biomarker of retinal structural degeneration
that was not attainable with the Visante® OCT. The Visante® OCT was only able to detect
significant thinning of only the whole retina at 10 months of age. When trying to
determine the factors that initiate early-onset retinal degeneration, assays at 10 months are
too late due to the progressive nature of the disease at this age.
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4.3. Retinal thinning is a global event that occurs throughout the hq mouse retina
The Spectralis® SD-OCT system was used to assess retinal degeneration from a
global and focal perspective by acquiring and comparing OCT images inferior, superior,
central and peripheral to the optic nerve in the hq mouse. There were no significant
differences in any of the retinal layer thicknesses indicating that early retinal thinning is
not a focal event consistent with experiments performed with Visante® OCT.26 This
suggests that an underlying retinal degenerative mechanism occurs across the retina.
There is no instance of outer nuclear layer thinning in a small foci of the retina relative to
the optic nerve. In vivo imaging with Spectralis® SD-OCT was successfully able to
acquire OCT images that demonstrated retinal thinning was consistent throughout the hq
mouse retina.

4.4. The use of in vivo imaging of the mouse is a popular technique to detect retinal
degeneration
Spectral-Domain OCT imaging is a common technique to assess structural
degeneration in the mouse retina. Imaging with similar OCT systems has been able to
detect thinning of the retinal layers specifically the outer nuclear layer in other mouse
models. A similar pathology to the hq mouse is the CCL2/CX3CR1-deficient mouse
which features a lesion that is initially detected in the inferior retina.92 The lesion is
followed by a progressive thinning of the retina marked by a thinning of the outer nuclear
layer.92 The CCL2/CX3CR1-deficient mouse has been considered a mouse model with a
similar pathology to AMD.93 In the case of the CCL2/CX3CR1-deficient mouse, a small
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lesion in one region eventually progressed to widespread retinal thinning and in vivo
imaging proved to be a valuable tool for early detection of focal changes.
The rd1 and rd10 mouse models have been used in studies to examine the
effectiveness of in vivo imaging to detect structural changes in the mouse retina.88,94 The
studies were able to detect thinning of the outer nuclear layer similar to this study of the
hq mouse.88,94 The studies were also able to compare retinal images from different areas
of the eye and assess global and focal changes.88,94 The effectiveness of in vivo techniques
in detecting retinal thinning is important when monitoring disease progression.
Efficacy of new drug therapies can also be monitored with the Spectralis® SDOCT. A drug progression study in human AMD patients was performed to measure
choroid neovascularization after treatment with the drug ranibizumab.95 The study used
the Spectralis® SD-OCT and the OCT images were very effective at identifying which
regions of the retina were altered following a drug treatment.95 The use of Spectralis® SDOCT with animal models can be a very effective tool when testing new drug compounds
on animal models. The ability to use non-invasive techniques offers an opportunity to
observe the living retina.

4.5. Spectralis® SD-OCT produces retinal images comparable to histological sections
The Visante® OCT system was previously used to assess structural changes in the
hq mouse retina and is unable to examine characteristics of structural degeneration
including cell losses and specific thinning of the retina. The Visante® OCT is able to
resolve an image of the retina, but not of the specific layers of the retina. The Visante®
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OCT has an axial resolution of 18 µm.96 Thinning of the whole retina can only be
detected, and there is no opportunity to examine specific regions across the retina. The
Visante® OCT produces a retinal image that comprises the central region where the
reference beam of light reaches. The Visante® OCT is an effective tool at examining the
anterior region of the mouse eye including the cornea and lens. The value of the
instrument is through the assessment of whether light is traveling through the anterior
structures to the posterior retina. The high resolution OCT image from Spectralis® SDOCT has an axial resolution of 7 µm and is able to resolve the individual retinal layers.96
The image obtained from Spectralis® SD-OCT has visibly distinct retinal layers
comparable to an image of a histological section. Comparisons of histological and
Spectralis® SD-OCT images have demonstrated a similarity between individual layer
thickness.97 Histological sections are the gold standard to observe and investigate the
nuclei of the mouse retina. The main advantages of high resolution in vivo imaging are
potential longitudinal studies with repeated imaging that are non-invasive leading to
lower animal numbers. A drawback is that only the histological sections are able to
resolve individual nuclei. This is a limitation of the technology as changes to specific
cells are not detected in the OCT images. However, the Spectralis® SD-OCT imaging
system is an effective tool to directly detect when retinal thinning occurs in specific
retinal layers.

4.6. The advantage of in vivo imaging of the mouse retina
An advantage of live in vivo imaging over histology when assessing disease
progression is that any cellular alterations post-euthanasia do not affect results. A recent
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study with OCT imaging of rat eyes examined whether changes occur in retinal structure
after euthanasia and whether these are visible in the images.98 The study showed that the
inner and outer segment of the photoreceptor layers is not easily identifiable after
euthanasia.98 These results suggest there may be a biological activity in the live
photoreceptor layer that is necessary to create a high resolution image of all the retinal
layers.98 Euthanasia and tissue storage and processing may compromise the biological
structure of the retina and the histological sections may portray structural changes that
may not be relevant to the living cell. Non-invasive in vivo imaging with Spectralis® SDOCT offers the opportunity to track changes within the living retina to monitor disease
progression and establish a biomarker of structural damage.

4.7. Increased numbers of microglial cells were observed in the hq retina at a young
age
Immunohistochemistry experiments showed significantly higher numbers of
microglial cells in the hq mouse retina at all age cohorts. Both functional and structural
markers were used to label microglial cells. At 1.8 months of age, the hq mouse retina
features greater numbers of microglial cells than wild-type indicating that the
parainflammatory response is active at a young age. The cell numbers peak at 4 months
and are unchanged at 7 months of age. These results show the response is initially active
before 1.8 months and continues to 4 months of age. When examining the hq timeline of
neurodegeneration, this time period correlates to decreases in ERG a-wave and b-wave
amplitude but precede the first appearance of photoreceptor cell losses.26
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4.8. The presence of microglial cells in the outer retina was observed in the hq mouse
The presence of microglial cells in the outer plexiform layer indicates that these
macrophage cells could have a detrimental effect on hq retinal function and structure.
Both the hq and wild-type mouse retinas have populations of active microglial cells with
an amoeboid morphology in the outer plexiform layer.69 The inner plexiform layer is the
location of the resting microglial cells that feature ramified processes.69 Although both
genotypes contain both the active and resting microglial cell populations, the hq retina has
greater activated cell numbers in the outer plexiform layer and the wild-type has more
resting microglial cells in the inner plexiform layer. The activated microglial cells in both
the hq and wild-type mouse outer plexiform layer are located on the border of the outer
nuclear layer. In the older age cohorts, specifically at 7 months of age, there also appears
to be microglial cells in the outer nuclear layer associated with the cell losses. The
location of microglial cells in the outer plexiform layer is consistent with the hypothesis
that upon activation, retinal microglial cells the hq mouse migrate from the inner retina to
the outer retina.99
The presence of microglial cells in the outer plexiform layer at 1.8 months
indicates that the cells could be responsible for the ERG a and b-wave reduction observed
in the hq retina.26 The location of microglial cells in the outer plexiform layer is also
associated with the amplitude deficits observed in the ERG oscillatory potentials of the hq
mouse. The oscillatory potential amplitude value is representative of the electrical
impulse transfer through the outer plexiform layer.100 A greater number of microglial cells
present in this region could be the reason for the observed signal impedance observed in
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the ERG.100 The phagocytic activity of the microglial cells is also a possible mechanism
for the structural losses observed at 4 months specifically in the outer nuclear layer.70 The
presence of cells that appear to be migrating through the outer retina indicates that the
microglial cells could be enveloping and destroying the photoreceptor nuclei in the outer
nuclear layer. The higher numbers, location and morphology of microglial cells is
consistent with a parainflammatory response.

4.9. Gene expression results indicate early activation of the parainflammatory
response
A two-fold increase of H2-K1 mRNA levels was observed in the hq mouse retina
at 1.8 months of age relative to wild-type. H2-K1 and !2M, had similar results at 4
months of age. The upregulation of the MHC-I complex indicates that the immune
response is active at a young age in the hq mouse retina. The mRNA levels in both H2-K1
and !2M are significantly increased ten and five-fold respectively at 7 months of age. The
results from the 7 month age cohort showed that the response is progressive as age
advances. The increased upregulation of MHC-I at this age is consistent with the
hypothesis that these genes are molecular markers of inflammation. This correlates with
in vivo imaging results that showed a significant thinning of the outer nuclear layer
between 4 and 7 months. The progressive structural losses that start as early as 4 months
of age in the hq retina support a hypothesis of a shift to a chronic response to
inflammation.
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4.10. The quantitative gene expression changes of Xanthine dehydrogenase were
inconsistent with previously observed microarray results
Quantitative gene expression results showed a modest increase in Xdh gene
expression at all age cohorts. There were no significant increases of Xdh mRNA levels
detected between hq and wild-type mouse retinas. These results indicate that the Xdh may
not be a suitable gene marker of the early parainflammatory response. Xdh was selected
based on the relationship with pro-inflammatory cytokines. The cytokine IFN-" has been
shown to regulate both XDH enzyme activity and expression of the Xdh gene in vitro in
rat cells.101 The ability of cytokines to increase XDH activity is believed to cause the
cytotoxic conditions due to ROS by-products from the enzyme.66 The production of ROS
through XDH activity may be a downstream effect of parainflammation with higher
enzyme activity at an older age. The modest fold-increases of Xdh gene expression
observed could also be higher than basal transcription levels. Another possibility is the
technical limitation of using a microarray when examining expression of a gene encoding
an enzyme. The effect of parainflammation may not involve increased expression of the
Xdh gene. There may be an increased activity of XDH in the hq mouse retina that is not
detected on a microarray. Another consideration is that of post-translational
modifications. XDH is readily converted to XO, which has been linked to ROS
production specifically superoxide.66 Both the microarray and Taqman® assay do not
measure enzyme activity of XO and the microarray data did not show a pattern of gene
upregulation related to increases in ROS.57
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4.11. Limitations of transcriptome data and qPCR confirmation
The results of studies with mass expression arrays have limitations in that data
may not be fully representative of the biological mechanisms being examined. The
expression arrays measure alterations in transcription that are upstream to both
translational and post-translational modifications that could have a greater influence on
both protein quantity and enzyme activity. The results observed in this study also
observed different fold changes for the same genes in both the microarray and qPCR
assays. The sources of these differences are possible technical issues involving different
primer designs and hybridization conditions between the two technologies. Limitations
considered, mass expression array and qPCR experiments still offer an opportunity to
explore trends and hypotheses on a wide-scale.

4.12. Gene expression changes are different in the retina compared to cerebellum
The fold-change increases of the MHC-I genes, H2-K1 and !2M were higher in
the retina when compared to the modest increases in expression in the cerebellum. These
results indicate that at the molecular level, the parainflammatory response is not as highly
active at a young age in the cerebellum as in the retina. The activation of microglial cells
and increases in MHC-I mRNA levels appear to occur first in the retina. However, a hq
mouse study observed activated microglial cells in the cerebellum as early as 2 months of
age which is similar to this retina study.27 The gene expression results indicate that
neurodegeneration occurs in the retina prior to the cerebellum in the hq mouse. The hq
mouse timeline of neurodegeneration in the cerebellum with the degeneration of neurites
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at 2 months followed by granule neuron degeneration at 4 months in the cerebellum
follows a similar pattern as the retina.27
The regulators of MHC-I transcription may influence the different expression
patterns observed between the retina and cerebellum. MHC-I genes are expressed on
nearly every nucleated cell and have conserved regulatory elements within the promoter
sequences.102 The transcription of MHC-I in both the brain and the retina depends on the
presence on specific families of transcription factors. The MHC-I promoter contains
enhancer binding sites that are bound by the NF-&B family.102 The NF-&B transcription
factors activate genes in response to infection and are primarily involved in immune
system regulation. An additional site found in the MHC-I promoter binds IFN-", the
signaling cytokine involved in pro-inflammatory responses.103 IFN-" has been shown to
have a crucial role in both basal and induced transcription of MHC-I.103 MHC-I
transcription is directly induced by IFN-" which is activated in the immune response.103
The microarray data from the 4 month hq mouse retina did not show any increases in
specific cytokine mRNA levels.57 The presence of different protein levels of IFN-" in the
cerebellum and retina may influence the different expression patterns of MHC-I observed
between the tissues. The microarray data showed upregulation of genes related to
inflammation with some of the genes activated by cytokines such as the gene Mx2 which
encodes a GTP-binding protein and a macrophage activator Gpb4 which are both induced
by IFN-".57 A study to quantify cytokine protein levels in the hq mouse retina and
cerebellum is a potential avenue to explore tissue differences.
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The hq mouse resembles a mitochondrial complex I disorder and there are
different activity patterns of complex I.30 The retina and cerebellum have been shown to
have 25% and 50% normal activity of complex I respectively.30 The reduced complex I
activity in the retina relative to other tissues led to a hypothesis of early activation of
parainflammation in the hq mouse. Observed increases in H2-K1 mRNA levels support
the hypothesis of increased expression of inflammation markers at a young age. The
lower activity of complex I in the hq mouse retina is associated with larger fold-changes
of the immune response complex at a young age when compared to the cerebellum.

4.13. The young hq retina has similarities to wild-type, aged mouse retinas
The hq mouse is a model of premature aging and the results of the gene expression
assay show that the hq retina has similarities to wild-type, aged retinas. At an advanced
age, an increased response to inflammation has been observed in wild-type mouse retinas.
Both H2-K1 and !2M are significantly upregulated two-fold in an older C57/BL mouse
(20 months) compared to a younger mouse (3 months).56 The hq retina has similar
increases of MHC-I genes gene mRNA levels as the 20-month-old C57/BL but at a much
younger age.56 The pathway analysis in the aged C57/BL retina showed that both the
immune and inflammatory response account for the highest number of differentially
expressed genes.56 The hq retina microarray also showed a large number of genes related
to inflammatory responses.57 There is a slow activation of the immune response genes in
the C57/BL mice seen with the MHC-I markers.56 In the absence of an injury, the increase
of MHC-I gene mRNA levels in the hq mouse retina appears to be very rapid. An
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additional gene expression study of the hq mouse olfactory epithelium showed no
significant fold-increases in inflammation-associated genes at 6 months of age.104 This
indicates that the response to inflammation may be more rapid in the retina than other
tissues in the hq mouse. The results show that H2-K1 and !2M are effective gene markers
of aged tissue due to the connection with other genes implicated in inflammation
pathways.

4.14. Increased expression of MHC-I genes demonstrates a greater population of
antigen presenting cells in the hq mouse retina
The increased mRNA abundances of MHC-I components in the hq mouse retina
indicates that there are higher numbers of antigen presenting cells at a young age.
Microglial cells possess the ability to express antigen presenting components encoded by
H2-K1 and !2M, making these genes markers of microglial activation.58 The early
upregulation of H2-K1 at 1.8 months indicates that microglial cells are active in the hq
mouse retina at a young age. The large fold changes observed at 7 months of age lead to
the hypothesis that there should be a larger population of microglial cells in the retina
when compared to the younger hq mouse age cohorts. This hypothesis was not met as
immunohistochemistry results demonstrated greater microglial cell populations in the
younger hq mouse age cohorts compared to 7 months.
The significance of the antigen presenting ability of microglial cells is the
initiating factors that activate the surface proteins. Microglia act as mediators of the
immune response through antigen presentation and the activation of MHC-I components
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below the outer nuclear layer.107 A rat model of inherited photoreceptor degeneration
showed that ganglion cell layer and inner plexiform layer resident microglial cells migrate
to the photoreceptors.108 The injured photoreceptors released a signal that initiated
microglial migration to the site of the injury.108 Microglial cells have the ability to destroy
photoreceptor cells both in vivo and in vitro and work to actively kill photoreceptors
which has been shown through the use of a microglial cell inhibitor.109 Blocking
microglial migration results in a higher survival rate of neurons, indicating that a
microglia directed inflammatory response is a mechanism of neuronal death.109
A study of human retinas from aged AMD and retinitis pigmentosa eyes showed
that the microglial response occurs after rod photoreceptor cell death.110 In these cases,
photoreceptor cell loss occurred in aged human retinas and appears to be a long-term
response effect.110 The microglial cells initial role is to act as a scavenger and phagocytose
debris present after photoreceptor cell death. Cytotoxicity is a result of the release of
nitric oxide and other molecules from microglial cells which causes the destruction of
adjacent photoreceptor cells.110 An initial recruitment of resident microglial cells to the
outer plexiform layer is associated with increased cytotoxicity of all photoreceptors in the
region. The observation of microglial cells in the region of photoreceptor cell losses at a
young age in the hq mouse retina is consistent with the hypothesis of early
parainflammatory response activation.
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4.16. Crosstalk with photoreceptors has been implicated in retinal microglial
activation
The thinning of the outer nuclear layer in the hq retina has also been observed in a
rat model of light-induced photoreceptor degeneration.111 Blue light exposure to the rat
retina and subsequent photic injury resulted in migration of microglial cells to the outer
nuclear layer.111 The study examined the influence on photoreceptor death of fractalkine,
a constitutively expressed CNS chemokine signaling molecule that binds to the CX3CR1
chemokine receptor present on microglial cell surfaces.111 Overexpression of fractalkine
corresponds with increases in photoreceptor survival. A reduced expression resulted in a
decreased inflammatory response.111 These results show that when there is a tissue injury,
there is a delicate balance of signaling factors that influence the microglial-mediated
inflammatory response.111 This study shows that crosstalk between neurons and
microglial cells has an influence on the scope of the response to inflammation. Microglial
cells are recruited by signals released from dying photoreceptor cells. A constant
recruitment of microglia is associated with cytotoxic effects observed in the hq mouse
retina.

4.17. Knockout of chemokine signaling results in a similar retinal degenerative
phenotype as the hq mouse
Mouse models with genetic manipulation of the chemokine signaling machinery
feature similar structural phenotypes in the the retina as a the hq mouse. A mouse with a
deletion of the chemokine receptor CX3CR1 features thinning of the outer nuclear layer
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and microglial activation in the outer plexiform layer.112 The structural degeneration
occurs at a much later age (18 to 24 months) than the hq mouse but the interesting finding
is that mutations to the microglial cells result in this phenotype. A mouse model that has a
double mutation that knocks out expression of both the CCL2 chemokine and the
CX3CR1 chemokine receptor shows similar cell losses of the outer nuclear layer than the
hq mouse with thinning initiating at 1 month.113 The formation of a lesion between 1.5
and 3 months of age in the double knockout has also been observed.92 The initial lesion
resembles the displacement event of cells from the outer nuclear layer towards the inner
segment observed in the hq mouse.92 The major difference is that the lesion is a focal
event that is detected in the inferior retina with an OCT.92 This study shows that the two
mutations result in a progressive degeneration of the photoreceptors layer by 8 months of
age.113 These two mouse models show a similar mechanism of structural retinal
degeneration as the hq mouse. The initial lesion suggests that similar structural
observations indicate similar initiating mechanisms. The lesion resembles nuclear
displacement in the outer segment observed in the hq mouse. The initial steps are similar
between mouse models with the chemokine knockout mouse having a more progressive
structural degeneration of the retina.92 The similarities suggest that the hq mouse could
have deficiencies in either chemokine receptors present on microglial cells or different
chemokine molecules.
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4.18. Blood-retina barrier breakdown is a potential inducer of chronic inflammation
in the hq mouse
The breakdown of the blood-retina barrier is a potential cause of the chronic
response to inflammation observed in the hq mouse retina. Disruption of the barrier
allows foreign material to enter the retina triggering immune response mechanisms.
During periods of ocular inflammation, lymphocytes cross the blood-retina barrier to
mount an immune response.114 The increases in microglial cell populations could also be
the result of the invasion of non-resident microglial cells from the brain.
Microglial cells localized to the outer plexiform layer and outer nuclear layer
could be present due to proximity to the choroid in the hq retina. The microglial cells act
as the first line of defense against foreign molecules and the photoreceptor layer is
adjacent to the choroid which is the source of the breakdown. The accumulation of
lymphocytes in the hq mouse retina is a topic to explore as a trigger of the chronic
response to inflammation. The nuclear displacement in the outer segment may be related
to an increased accumulation of lymphocytes in the hq mouse retina. An assay for the
presence and location of lymphocytes is a potential experiment to examine whether there
is an accumulation of foreign cells in the parainflammatory response.
An additional mechanism of the breakdown of the blood-retina barrier has been
observed in an in vitro study of the interaction of microglial cells and the RPE.84 When
microglial cells were added to a culture of RPE cells, the result was an increase in choroid
neovascularization.84 Choroid neovascularization occurs in AMD but the key finding is
that microglial cells in the subretinal space are able to induce this process.84 Choroid
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neovascularization has not been observed in the hq mouse retina as old as 10 months,
making it unlikely to be a contributing factor.26 The microglial cells may be able to
promote additional breakdown of the blood-retina barrier related to increased
inflammatory responses.

4.19. Location of microglial cells at the outer nuclear layer may be due to
mitochondrial dysfunction
Among the previously mentioned mouse models, it appears that microglial cells
are commonly located at the site of photoreceptor degeneration but the reason is not well
understood. Photoreceptors are mitochondrial rich cells and mitochondria are located at
the axon terminal of the photoreceptor cells in mouse, humans and rats.115 The axon
terminal is located in the outer plexiform layer, which is the location of the microglial
cells in the hq mouse retina. The effect of Aif downregulation may influence the response
of parainflammation to manifest itself in the outer plexiform layer due to abundance of
mitochondria.
Mitochondrial oxidative stress has been identified in several inherited
photoreceptor disorders. A mutation in mitochondrial complex V has been linked with
cases of retinitis pigmentosa in human patients.116 Mouse models of photoreceptor
degeneration feature reduced complex I activity in the retina which is similar to the hq
mouse.117 This shows that there is a possibility that the Aif downregulation creates
favourable conditions for microglial cells to migrate to the outer plexiform layer. These
conditions include an increase in oxidative stress causing photoreceptor degeneration and
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pro-inflammatory signal release which has been observed in animal models.111 A rat
model of intraocular inflammation, known as experimental autoimmune uveitis, showed
increases of both oxidative and nitrogen stress in the photoreceptor mitochondria.118
Subsequently, microglial cells were activated and mediated the immune response.118 The
mode of activation represented in these animal models may involve an initial spike in
oxidative stress in photoreceptor cells which releases pro-inflammatory factors such as
chemokines to activate microglial cells. The mitochondrial dysfunction in the hq mouse
appears to manifest itself in the outer plexiform layer and pro-inflammatory signals
mediate the subsequent death of the photoreceptor cells.

4.20. Anti-inflammatory therapy may reduce microglial activation
A potential avenue to explore with the hq mouse is whether an anti-inflammatory
therapy is able to slow or eliminate early-onset retinal degeneration. A drug of interest is
the tetracycline derivative, minocycline, which has been shown to possess a
neuroprotective ability and is able to suppress microglial activation.119 A study of the
effect of minocycline on the DBA/2J mouse, a model of glaucoma, showed a reduction of
microglial activation after a progressive therapy.119 The results were an increase in resting
microglial cells along with an overall reduction of cell population.119 The rate of ganglion
cell death, which is the major pathological event of glaucoma mediated by microglial
activation, was also reduced.119 The early activation of microglial cells in the hq mouse
retina has identified a suitable drug target to test with minocycline. If treatment of hq
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mice is able to slow down retinal degeneration, then the parainflammatory response could
be considered a major disease causing mechanism.

4.21. Therapy to restore mitochondrial function to prevent retinal degeneration
While the hq model may help select an appropriate anti-inflammatory drug, a
therapeutic intervention that targets the parainflammatory response may not be effective
due to the downstream responses. The response to inflammation may be a result of
mitochondrial dysfunction and an anti-inflammatory therapy would not be targeting the
source. There are several strategies to target mitochondrial dysfunction in the eye that are
still in the stages before human clinical trials. Gene therapy techniques have shown initial
promising results in proof of principle experiments. A strategy to restore mitochondrial
function is to restore or increase anti-oxidant enzyme activity. The transfection of a
human superoxide dismutase (sod2) gene has been shown in vitro and in vivo to prevent
retinal ganglion cell death by decreasing levels of free radicals.120, 121 Another therapy is
an allotopic rescue which replaces a mitochondrial complex subunit. Visual function was
restored in rats after integration of a wild-type ND4 gene by electroporation into retinal
ganglion cells.122 ND4 encodes an NADH dehydrogenase subunit found in the
mitochondrial complex I.122 Allotopic therapies offer a potential method of restoring the
function of defective mitochondria including the hq mouse which features a low complex
I activity.
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4.22. The hq mouse exhibits characteristics of an early, active response to
parainflammation
The central hypothesis of an active parainflammatory response at a young age in
the hq mouse retina was supported by quantitative gene expression and
immunohistochemistry experiments. The earliest structural biomarker of retinal thinning,
specifically that of the outer nuclear layer, was observed in vivo between 4 and 7 months
of age. Gene expression assays showed increased transcript levels of the MHC-I
components at 1.8 months indicating a response to parainflammation was active at a
young age. The activation of microglial cells at a young age and subsequent increase in
cell populations over time was observed. The microglial cells represent a major
component of the immune response to parainflammation. The location of these cells
adjacent to the site of retinal structural degeneration in the hq mouse offers a mechanism
of early-onset retinal degeneration. The main initiator of microglial cell mediated
photoreceptor degeneration has yet to be determined. The results of this study have
narrowed the path to explore the causal effects of hq retinal degenerative disease.

4.23. Conclusion
This study has demonstrated an association between a parainflammatory response
and the early-onset retinal degenerative phenotype of the hq mouse. The link between
mitochondrial dysfunction in the hq mouse photoreceptor cells and the initiation of the
parainflammatory response is the next step in uncovering the initiators of retinal
degeneration. The identification of the signaling molecules or pathways initially activated
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in the hq mouse model of premature aging is the key to understanding retinal
degenerative mechanisms. There are many diseases that affect the eye in many forms.
Inflammation in the retina is a common thread of major retinal degenerative diseases and
immune response activators are potential drug targets to slow or prevent degeneration to
improve quality of life for people suffering from vision loss.
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Appendix A- The University of Western Ontario Ethics Approval for Animal Use in
Research

This appendix contains documentation of the ethics approval form for animal use in the
Hill laboratory from the University Council on Animal Care and the Animal Use
subcommittee.
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Appendix B- Supplementary Tables and Figures

This appendix features supplementary tables and figures to assist in understanding the
data presented in the study.
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Table B1. List of primers used in PCR experiments.
!
!
!
!
!
!
!
!
Target
Length (bp)

Aif

Primer Position

!

!

Sequence (5’-3’)

Forward

CTATGCCCTTCTCCATGTAGTT

Reverse

AGTGTCCAGTCAAAGTACCGGG

Proviral Forward

GAACAAGGAAGTACAGAGAGGC

!

!
Amplicon

537 (WT)

725 (hq)
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Table B2. Retinal and cerebellar RNA sample concentrations.

Sample

Genotype

Age
(Months)

Retinal RNA
Cerebellar RNA
Concentration (ng/μl) Concentration (ng/μl)

919.20

WT

1.8

114

110

919.24

WT

1.8

106

103

A02.21

WT

1.8

155

118

919.28

WT

1.8

N/A

121

919.36

XhqY

1.8

102

N/A

919.40

XhqY

1.8

113

225

919.30

XhqY

1.8

97

102

919.33

XhqY

1.8

132

115

919.15

WT

4

213

142

A02.17

WT

4

112

122

A01.98

WT

4

599

167

E01.12

XhqY

4

105

N/A

E01.13

XhqY

4

112

101

922.25

XhqY

4

N/A

130

A02.12

XhqY

4

599

N/A

918.19

WT

7

109

100
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Sample Genotype

Age
(Months)

Retinal RNA
Cerebellar RNA
Concentration (ng/μl) Concentration (ng/μl)

918.18

WT

7

N/A

106

920.7

WT

7

270

N/A

920.4

WT

7

30

N/A

918.26

XhqY

7

103

N/A

918.8

XhqY

7

471

N/A

918.12

XhqY

7

106

102

918.14

XhqY

7

101

114

918.20

XhqY

7

137
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Figure B.1. Diagram of the Taqman® qPCR experimental design. The 72 well plate
was divided into 4 sections with each colour representing a different mouse cDNA sample
(XhqY- hq disease, WT- wild-type mouse). Each letter represents the Taqman® probe used
in the well. The No-Template Control wells did not contain any mouse cDNA. Each gene
of interest was assayed in triplicate for each mouse cDNA sample.
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Figure B.2. Selection of final antibody concentration was determined following
dilution series of primary and secondary antibodies. A dilution series experiment was
performed to optimize the final concentration and to confirm the specificity of the antiIba1 for microglial cells. The selected tissue was 21 month-old wild-type mouse
cerebellum. The dilution series consisted of (A) 1:100 primary antibody and 1:500
secondary antibody concentration. (B) 1:250 primary antibody and 1:500 secondary
antibody concentration. (C) 1:250 primary antibody and 1:1000 secondary antibody
concentration. (D) Negative control of a 21 month-old wild-type mouse cerebellum that
was not treated with the primary antibody anti-Iba1. The white arrows are directed at
microglial cells. ImageJ® software was used to better quantify secondary antibody signal
intensity.
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Figure B.3. Specificity of the anti-F4/80 primary antibody was demonstrated in wildtype mouse spleen. Spleen from a 7 month-old wild type mouse was used to assess the
specificity of the anti-F4/80 primary antibody for microglial cells. (A) A mouse splenic
tissue section treated with a primary antibody concentration of 1:100 and a secondary
antibody concentration of 1:500. (B) A mouse splenic tissue section that was not treated
with primary antibody but treated with a 1:500 concentration of secondary antibody.
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